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Hepatitis C virus (HCV) infection is a serious and continuing threat to human 
health. The infection by the HCV can lead to liver cirrhosis and eventually 
hepatocellular carcinoma, which often results in death. Recently efforts have 
been concentrated towards developing direct acting agents (DAA’s) targeting 
several gene products of HCV. Among several gene products of HCV, non-
structural protein 5A (NS5A) is known to be essential for HCV proliferation 
and considerable efforts have been made in developing anti-HCV drugs 
targeting NS5A. We report in this thesis the discovery of a new series of potent 
hepatitis C virus non-structural protein 5A (NS5A) inhibitors containing biaryl 
sulfone or sulfate cores and substituted fluorenyl cores.  
First, for the synthesis of HCV NS5A inhibitors containing a sulfate core 
structure, highly efficient, chemoselective coupling reactions between an 
arylsulfonyl fluoride and an aryl silyl ether, known as the sulfur(VI) fluoride 
exchange (SuFEx) reaction, were utilized. Among the inhibitors prepared based 
on the SuFEx chemistry, several compounds exhibited two-digit picomolar 
EC50 values against GT-1b and single digit or sub-nanomolar activities against 
HCV GT-2a strain. Nonsymmetrical inhibitors containing an imidazole and 
amide moieties on each side of the sulfate core structures were also synthesized. 
Structure-activity relationship (SAR) studies on inhibitors containing various 
substitution patterns of the sulfate or sulfone core structure established that 
m-,m’- substituted biaryl sulfate core-based inhibitors containing an amide 
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moiety (BMK-21014) or an imidazole moiety (BMK-21025) showed 
extremely high potency. BMK-21014 demonstrated double-digit pM potencies 
against both genotype 1b (GT-1b) and 2a (GT-2a). BMK-21025 also exhibited 
double-digit pM potencies against GT-1b and sub nM potencies against GT-2a. 
Furthermore, BMK-21014 and BMK-21025 exhibited no cardiotoxicity in an 
hERG ligand binding assay and showed acceptable plasma stability and no 
mutagenic potential in the Ames test. In addition, these compounds showed 
distinctive additive effects in combination treatment with the non-structural 
protein 5B (NS5B) targeting drug sofosbuvir (Sovaldi®). The results of this 
study showed that the BMK-21014 and BMK-21025 could be effective HCV 
inhibitors.  
In addition, a biotinylated probe targeting NS5A protein was prepared for 
labeling using the same synthetic methodology. These compounds also showed 
higher inhibitory effects than previously reported compounds. These results 
showed that compounds with biaryl sulfate core skeleton could be effective 
HCV inhibitors.  
While several NS5A inhibitors in combination with inhibitors of other gene 
products have been effective, NS5A inhibitor resistances caused by mutants 
have become a major issue. To overcome the low efficacy of known inhibitors 
on a specific genotype and the low resistance barrier, we have generated many 
different derivatives of NS5A inhibitors and investigated their effects on HCV 
proliferation using in vitro as well as in vivo assay systems. Among several 
different types of inhibitors, we generated NS5A inhibitors with fluorene 
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prolinamide structures and found that they are highly effective on resistance 
mutants HCV or pan-genotype HCV. Also, we identified a close structure 
activity relationship (SAR) between the specific part of compounds such as 
fluorene core or L-proline derivatives towards daclatasvir resistance mutants. 
From this study, we developed compounds BMK-21054 and BMK-21075 that 
are effective for genotype 3a and drug resistance mutants. Based on these 
results, we were able to identify new NS5A inhibitors containing the fluorene 
core skeleton and substituted L-proline derivatives, which exhibit excellent 
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1. Introduction  
HCV affects essential liver health leading to infectious hepatitis.[1, 2] Since the 
first identification of HCV in 1989, approximately 3 to 4 million people are 
newly infected annually and 160-200 million people have been infected 
worldwide so far. Nearly 20 percent of those patients develop liver cirrhosis 
and some eventually hepatocellular carcinoma (HCC).[3, 4] In 2014, the World 
Health Organization (WHO) announced that hepatitis C-related liver diseases 
kill 350-500 thousand people each year.[5] 
Most people were mainly infected the HCV through contact with the blood of 
an infected person such as the use of non-sterile apparatuses, heterosexual 
contact and blood transfusion.[6] The possibility of diagnosing the HCV RNA 
level 1~3 weeks after infection and no symptoms in the early stages of the 
disease have made the infected patients increase rapidly.[6] 
To date, HCV strain has been classified into 7 genotypes and about 70 
subtypes. Because of the intrinsic lack of proof-reading of HCV RNA 
dependent RNA polymerase (RDRP), genomic diversity of HCV has grown. 
According to recent estimates, genotype 1a and 1b are distributed mostly 
(46.2%) in the world, followed by genotype 3 (30.1%). Genotypes 2, 4 and 6 
account for 22.8% of all HCV cases.[7] 
HCV is an encased RNA virus in the Flaviviridae family comprising of a 9.6-
kb single (+) strand RNA.[8] The genome of HCV consists of a single open 
reading frame (ORF) containing 9024~9111 nucleotides.[9] This genome 
encodes 10 proteins which are synthesized in double membranous vesicle and 
translated into cytosol by binding of host translation initiation factors on 
internal ribosome entry site (IRES) region of 5’ untranslated region (UTR).[10] 
The translated polyprotein is made up with about 3,000 amino acid, which is 
cleaved to non-structural (P7, NS2, NS3, 4A, NS4B, NS5A, and NS5B) 
proteins and structural (Core, E1 and E2) proteins by both viral and cellular 
proteases, which are necessary for viral proliferation.[11] 
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The core protein and two envelope glycoproteins (E1 and E2) are structural 
proteins which form the viral nucleocapsid by surrounding the HCV RNA 
genome. The p7 transmembrane polypeptide, which form the hexamers and 
regulate the ion-channel activity, play a crucial role for viral particle maturation 
and release.[12] The NS2 cysteine protease participate in cleavage the NS2-NS3 
junction in the polyprotein. And it also regulates cell cycle and proliferation for 
the host cell.[13] The NS3 has two enzymatic roles: N-terminal protease and a 
C-terminal helicase.[13] Especially, serine protease domain in NS3 play an 
important role in the cleavage of four junctions in HCV polyprotein.[14] NS4A 
is cofactor of NS3 protease and NS4B is an integral membrane protein having 
four transmembrane domains that participate in establishment the membranous 
web.[6] The NS5A protein is about 447-amino acid, hydrophilic phosphorylated 
zinc- metalloprotein. It conducts formation of RNA replication complex and 
assembly for new virions. The NS5B is the RNA dependent RNA polymerase 
(RDRP), which fulfills the replication of the HCV RNA using the positive RNA 
strands.[15] 
 
2. Non-structural 5A protein 
NS5A is known as a non-enzymatic, multifunctional protein involved in viral 
replication and assembly.[16] Though it has no enzymatic activity, it is essential 
for the formation of RNA replication complex.[17] It regulates virus particle 
assembly in a phosphorylation dependent manner.[18] NS5A is phosphorylated 
by cellular kinases to the basal and hyper phosphorylated form in order to 
regulate virus life cycle.[19] NS5A protein has several interactions with host 
factors that lead to developing of liver disease such as carcinoma.[20, 21] NS5A 
consists of three distinct domains I, II and Ⅲ. Especially, domain I and II are 
involved in RNA replication and domain Ⅲ is region that related to package 





Figure 1. X-ray crystal structures of NS5A protein. (a) Open form (PDB : 
1ZH1) (b) Closed form (PDB : 3FQQ). 
 
Two X-ray crystal structures of NS5A protein were revealed for the domain Ⅰ 
of NS5A excluding 1~31 amino acids, which consist of the amphipathic alpha 
helix region (AH) at the N-terminal part (figure 1).[21] However, full form of 
NS5A domain 1 structure has not been elucidated yet.[3, 22] 
Recently, biochemical studies suggested a mechanism of action for NS5A 
inhibitor. It is reported that potent NS5A inhibitors block the viral replication 
by interrupting the formation of membranous web at an early stage in virus 
replication cycle.[23] In addition, in-vitro analysis has shown that NS5A 
inhibitors appear to compete with HCV RNA for binding purified NS5A 
protein. However, resistance mutant forms of NS5A protein reduced binding 
affinity with NS5A inhibitor. Subsequently, in-silico docking studies were 






3. Development of NS5A inhibitors 
In accordance with international therapy guidelines, the first standard of care 
(SOC) against HCV comprised a combination of pegylated interferon (PEG-
IFN) α series (α2a or α2b) and ribavirin (RBV), a nucleoside-type drug.[25, 26]  
Nevertheless, this remedy has not only 50% cure rate for the common GT-1 
patients, but also other severe adverse effects such as insomnia, depression, 
neutropenia, flu-like symptoms, fatigue, lymphopenia, and other unexpected 
drug interactions.[27, 28] Therefore, many pharmaceutical companies and 
laboratories worldwide have widely studied Direct Acting Antivirals (DAA’s) 
as next-generation therapies to overcome drawbacks of conventional 
treatments.[21] DAAs therapies have higher SVR rate to HCV compared to IFN-
based therapy and are found to be relatively safer than the IFN treatments.[14] 
The major targets of DAAs are NS3/4A protease, NS5B RNA-dependent RNA 
polymerase (RDRP) and NS5A protein.[29, 30] Because of non-enzymatic 
property, the NS5A protein was not attractive target protein for early stage in 
drug discovery. However, replicon systems demonstrated that NS5A functions 




Figure 2. Structure of NS5A inhibitors in market or clinical trials. 
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Currently, six NS5A inhibitors are on the market for use with ribavirin, 
NS3/NS4A protease inhibitors, or NS5B inhibitors.[32] In 2014, the US Food 
and Drug Administration (FDA) approved ledipasvir (GS-5885) with the NS5B 
inhibitor, sofosbuvir.[33] Ombitasvir (ABT-267) was also approved by the FDA 
in combination with paritaprevir (NS3/4A protease inhibitor), ritonavir 
(protease inhibitor), and dasabuvir (NS5B inhibitor) for HCV genotype 1 
infections.[34] Daclatasvir (BMS-790052) in combination with sofosbuvir 
(2015), elbasvir (MK-8742) in combination with grazoprevir (NS3/4A protease 
inhibitor), and velpatasvir (GS-5816) along with sofosbuvir in 2016 are among 
another FDA-approved HCV DAAs.[35] Recently, the FDA approved Vosevi®  
in 2017, which is a combination of sofosbuvir, velpatasvir, and voxilaprevir 
(NS3/4A inhibitor); a new pan-genotype drug, Mavyret®  
(glecaprevir/pibrentasvir), was also approved in the same year.[36] 
A new NS5A inhibitor, daclatasvir (BMS790052, Daklinza® ), was first 
reported in 2010 and approved in Europe in 2014 (Figure 2). As a suppressor 
of the NS5A replication complex, daclatasvir showed impressive results at 
single-digit picomolar effective concentrations (EC50) (9 pM and 50 pM against 
GT-1b and GT-1a, respectively). It effected 2-fold decreases in levels of viral 
RNA within 6 h of oral administration in clinical trials.[37, 38] Consequently, the 
NS5A phosphoprotein became one of the most desirable drug targets of HCV 
for many pharmaceutical companies.[38] 
Daclatasvir has a C-2 symmetric structure that consists of a biphenyl core 
linked to a 2-(1H-imidazol-2-yl)-pyrrolidine moiety, and an N-
(methoxycarbonyl)-L-valine capping group (Figure 2). In particular, the 
imidazole and carbamate groups play an important role in the interaction of 
daclatasvir with the HCV NS5A complex.[39, 40] Although daclatasvir had no 
reported serious side-effects or drug-drug interactions (DDI), resistance to the 
drug appeared in patients infected with GT-1a and GT1-b HCV.[20] The main 
amino acid mutations were Y93H and L31V in GT-1b, which resulted in 19-
fold and 23-fold increases in resistance to daclatasvir, respectively.[41] When 
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there was combination of both Y93H and L31V mutations in GT-1b, resistance 
to daclatasvir increased 8,336-fold. To address this issue, many research groups 
















Development of potent HCV NS5A 
inhibitors based on a biaryl sulfate 










Figure 3. Strategy for designing new potent HCV NS5A inhibitors. 
 
Our laboratory reported a series of NS5A inhibitors represented by BMK-
20113 (EC50 against GT-1b and GT-2a strains: 28 pM and 260 pM, 
respectively), which comprises a benzidine prolinamide skeleton and an N-
(methoxycarbonyl)-D-phenylglycine based capping group (Figure 3).[15] 
Y. A. Ivanenkov and coworkers reported that the length between chiral 
carbons of two capping groups in NS5A inhibitors having high inhibitory 
activities are 19 ~ 21 Å  by calculation in silico.[42] Considering the structural 
features of BMK-20113, we hypothesized that a longer biaryl core might 
improve the inhibitory activity of the HCV NS5A replication complex as shown 




Table 1. In silico calculation of the distance between two capping 









4.00  16.4 Å  
 
4.09  17.3 Å  
 
4.36 17.9 Å  
 
3.27 18.2 Å  
 
3.43 19.8 Å  
Daclatasvir (BMS-790052) 4.58 17.5 Å  
Ombitasvir (ABT-267) 5.60 18.5 Å  
Elbasvir (MK-8742) 6.02 19.0 Å  
Ledipasvir (GS-5885) 5.57 22.3 Å  
Samatasvir (IDX-719) 6.42 20.5 Å  
aALOGPS 2.1 
bLength is the distance between two chiral centers of capping groups 
cSpartan (v14, B3LYP, 6-31G*) 
 
We calculated the lengths between two capping group stereogenic centers in 
BMK series inhibitors and commercial drugs for the purpose of finding optimal 
distance of the optimized core structure (Table 1). In addition, we investigated 
the logP values to predict the solubility of the inhibitor compounds. Finally, the 
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NS5A inhibitors equipped with biaryl sulfone or sulfate core structures showed 
optimal scores for the length and logP in silico. 
Herein, we report the design and synthesis of new NS5A inhibitors embedding 
biaryl sulfone or sulfate core structures (Ar-SO2-Ar, ArO-SO2-OAr) with 
imidazole or amide connections.  
 
 
Figure 4. Biaryl sulfate core based nonstructural 5A (NS5A) inhibitors and 
modification using sulfur(VI) fluoride exchange (SuFEx) chemistry. 
 
We also optimized the biaryl sulfate core part and carried out further SAR 
studies based on the sulfate core structures. During this investigation, we 
discovered that some substituted biaryl sulfate core structures were not readily 
accessible from traditional coupling reactions with sulfonyl diimidazole (SDI). 
For example, in the cross-coupling reactions of o-fluorophenol derivatives with 
SDI, only a monomeric aryloxy sulfonyl imidazole was obtained. Likewise, the 
sulfonyl diimidazole coupling strategy would not be appropriate for selective 
construction of nonsymmetrical biaryl sulfate core structures (Figure 4).[43] 
20 
 
Although the first-generation DAA’s HCV drugs have symmetrical structures 
similar to daclatasvir, many next-generation DAA’s developed to treat multi-
genotype strains tend to possess nonsymmetric structures.[42, 44] Since there have 
been reports of NS5A inhibitors with a high degree of variation at the center 
core, we envisioned that nonsymmetrical biaryl sulfate core structures with 
substituted aryl groups would be worth investigating and, thus, were included 
in our SAR studies.[39, 45] For the synthesis of the nonsymmetrical biaryl sulfate 
core structures, SuFEx chemistry appeared to be an extremely attractive 
strategy.[46] Therefore, we report the fruitful exploitation of SuFEx chemistry 
for the construction of symmetrical and nonsymmetrical biaryl sulfate-based 
HCV NS5A inhibitors, which exhibit extremely high inhibitory activities. 
In 2014, Sharpless and coworkers introduced the SuFEx click reaction for 
chemoselectively linking two different phenol derivatives.[47] The sulfate 
coupling reaction was accomplished through the reaction of an aryl 
fluorosulfate and an aryl silyl ether in the presence of a catalytic amount of 1,8-
diazabicyclo(5.4.0) undec-7-ene (DBU).[47, 48] The synthesis of sulfate 
compounds from the SVI-F group proceeded with high yields and at a fast rate 
because of the driving force that formed the strong Si-F and S-O bond.[48] 
Furthermore, the resulting compounds exhibited considerably high stabilities 
against hydrolysis, nucleophilic substitution, thermolysis, and reduction.[49, 50] 
Moreover, this useful coupling reaction produces only inert silyl fluorides as 
by-products.[49-52] We envisioned that this chemoselective SuFEx reaction could 
be used for the synthesis of novel HCV NS5A inhibitors containing biaryl 
sulfates possessing various substitution at the o-position of the phenol 





2. Results and Discussion 
 
Scheme 1. Synthesis of NS5A inhibitors; reagents and conditions: (a) EDCI, 
N-Boc-L-proline, CH2Cl2, rt, 4 h, 44%; (b) TFA, CH2Cl2, rt, 30 m; (c) HOBt, 
EDCI, DIPEA, Capping group, CH2Cl2, rt, 16 h, 50-55% 
 
Compounds containing a biaryl sulfone core were prepared following a 
general amide synthesis procedure as shown in Scheme 1.[33] Coupling of 4,4'-
diaminodiphenyl sulfone 1 with N-Boc-L-proline in the presence of 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDCI) provided N-Boc-protected 
intermediate 2 in moderate yield (44%). After removal of the Boc group, free 
amine moieties were coupled with D-phenylglycine, D-valine, or L-valine, each 
of which was capped with an N-(methoxycarbonyl) group[53] furnishing the 





Scheme 2. Synthesis of intermediates; reagents and conditions: (a) Pd/C, H2, 
MeOH, rt, 24 h, 99%; (b) EDCI, N-Boc-L-proline, CH2Cl2, rt, 4 h, 59-99%. 
 
Synthesis of prolinamide precursors 5a-f for the sulfate class inhibitors was 
accomplished according to Scheme 2. Various aminophenol derivatives (4a-f), 
which were either commercially available or prepared from reduction (Pd/C, 
H2) of nitrophenol derivatives 3a-c, were coupled with N-Boc-L-proline 
through a standard amide coupling method to yield prolinamide derivatives 5a-




Scheme 3. Synthesis of intermediates; reagents and conditions: (a) CuBr2, 
EA/CHCl3, reflux, 8 h, 81%; (b) N-Boc-L-proline, N,N-Diisopropylethylamine 
(DIPEA), acetonitrile, rt, 5 h, 72–91%; (c) NH4OAc, toluene, 95 ℃, 20 h, 45–
52%. 
 
We also prepared various imidazole-containing phenol derivatives (9a-c) as 
substrates for the SuFEx reaction (Scheme 3).[33, 55] The imidazole-linked 
monomers 7a-c were prepared from the acetophenone derivatives following an 
established procedure.[40] -Bromination of acetophenone 6 was carried out in 
the presence of copper(II) bromide to provide -bromoacetophenone 7a in an 
81% yield.[56] Then, the resulting product 7a-c was treated with N-Boc-L-
proline in the presence of DIPEA to yield ester 8a.[40] Likewise, commercially 
available -bromoacetophenone derivatives 7b and 7c were converted to the 
corresponding esters 8b and 8c, respectively. Synthesis of the imidazole 
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derivatives 9a-c was accomplished by the reaction of 8a-c with ammonium 
acetate.[40] 
 
























a Yields of isolated products. 
 
The introduction of a fluorosulfonyl (fosyl) group was achieved by the 
reaction of the corresponding phenol derivatives with sulfuryl fluoride (SO2F2) 
and 1.7 equiv DIPEA in dichloromethane (Table 2).[48] Since SO2F2 is a gas, the 
reaction mixture was stirred rapidly (> 1,000 rpm) to enhance the liquid-gas 
contact.[50] The reaction was complete within 5 h, monitored using thin layer 
chromatography (TLC). The structures of the fosylated products were 
confirmed using proton (1H), 13C, and 19F nuclear magnetic resonance (NMR) 
spectroscopy; especially, 19F NMR chemical shifts of fluorine at fosyl group 
ranged from ca. 31 to 40 ppm.[57] These fluorosulfate derivatives exhibited good 
stability against hydrolysis and could be stored on the shelf for months.[58] 
Compounds 10a-g were obtained in good yields (> 80%) as shown in Table 2. 
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Table 3. Preparation of biaryl sulfate core structures using sulfur(VI) 
































aYields of isolated products. 




We then constructed the sulfate core structures using aryl silyl ether 
counterparts through SuFEx chemistry (Table 3).[51] Silylation of phenol groups 
was achieved using the standard method with tert-butyldimethylsilyl chloride 
(TBDMSCl) and imidazole.[59] The coupling reaction between an aryl fosylate 
and aryl silyl ether was carried out in the presence of DBU in dimethyl 
formamide (DMF) according to Sharpless’ protocol.[46, 48] Then, the mixture 
was stirred at 50 oC for 12 h. The biaryl sulfate products (compounds 12a-f) 
were formed in good to excellent yields in the presence of catalytic amounts of 
DBU (20-30 mol%).[46, 48] However, in case of the coupling reactions involving 
the silyl ether or fluorosulfate monomer containing an imidazole moiety 
(compounds 12g-j), 2.2-2.3 equiv DBU was used for the SuFEx coupling 
products. 
We synthesized biaryl sulfate based NS5A inhibitors using appropriate 
precursors. The tert-butyloxycarbonyl (Boc)-protecting group for the proline 
moiety was deprotected with 50% (v/v) TFA in CH2Cl2.
[15] Volatiles were 
removed from the reaction mixture under reduced pressure and the residue was 
directly coupled with a capping group such as N-methyloxycarbonyl-protected 
valine (val) or phenylglycine (phg) in the presence of EDCI and HOBt.[60] 
Finally, the biaryl sulfate based HCV NS5A inhibitors were obtained after 
purification of the crude products using silica gel chromatography.[60]  
To determine the antiviral activities of each compound, we measured the EC50 
of inhibitors for genotype-1b (GT-1b) and 2a (GT-2a) using the HCV replicon 
and HCV cell culture (HCVcc) systems, respectively.[53] We used the human 
hepatoma Huh 7.5.1 cell line to investigate the EC50 of the compounds in the 
HCV replicon systems for GT-1b, which encodes the bicistronic NK5.1 gene 
and Gaussia luciferase (Gluc) reporter gene.[61] 
On the other hand, the inhibitory activities of GT-2a were measured using 
the HCVcc system with JFH 5a-Rluc-ad34, which is a derivative of JFH5a-
Rluc-ad34 (a variant of JFH1 with 2 cell culture-adaptive mutations) was added 
to Huh7.5.1.[62] After infection for 4 h, Huh7.5.1 cells were added to culture 
medium containing compounds of interest at different concentrations. After the 
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cells were incubated for 3 d, EC50 values of compounds were measured using 
luciferase assays.[53, 63] 
 
Table 4. In vitro activities of inhibitors containing a p-,p’-disubstituted biaryl 














36.1 - > 30 
14 
(BMK-21056)   
> 105 - > 30 
15 
(BMK-21033)   
> 105 - > 30 
16 
(BMK-21057)   
2,570 - > 30 
17 
(BMK-21013)   








0.270 0.147 > 30 
20 
(BMK-21015)   




(BMK-21030)   
4.26 - > 30 
 
The EC50 values of tested compounds against GT-1b and GT-2a are listed in 
Table 4. Compounds showing good potencies against GT-1b were selected for 
further testing against GT-2a. The inhibitory activity of compound 13, which 
features a biarylsulfone core with a D-phenylglycine capping group was 36.05 
nM against GT-1b, whereas both 14 and 15, which contain valine isomers, 
showed no apparent inhibitory activities against GT-1b. Since the inhibitors 
containing a biaryl sulfone core did not appear to be effective as NS5A 
inhibitors, compounds with a biaryl sulfate core were examined. compound 16 
containing a biaryl sulfate core with an L-valine capping group exhibited poor 
inhibitory activity in the GT-1b assay. When the L-valine moiety compound 16 
was replaced with an enantiomer 17, a slight increase in inhibition (EC50 574.8 
nM) was observed. The inhibitory activities of compound 15 and 17 provide a 
direct comparison of the influence between the sulfone and sulfate core 
structures and appear to indicate that the sulfate core is more effective. However, 
when the D-valine residue in 17 was replaced by a D-phenylglycine moiety as 
in compound 18, excellent sub nanomolar activities were observed in both GT-
1b and GT-2a assays. The replacement of the amide moiety in compound 18 
with an imidazole ring as in compound 19, a replacement that may improve the 
water solubility of the inhibitor molecule, decreased the inhibitory activity 27-
fold in the GT-1b assay. Likewise, similar inhibitory activity was observed for 
compound 20 and 17 in the GT-1b assay. However, the L-valine diastereomer 




Table 5. In vitro activities of inhibitors containing an m-,m’-disubstituted 














R1 = H 
R2 = H 
 
0.0198 0.0199 > 30 
23 
(BMK-21042) 
R1 = H 
R2 = H  
0.0772 0.943 > 30 
24 
(BMK-21019) 
R1 = H 
R2 = H 
 
0.360 10.0 > 30 
25 
(BMK-21032) 
R1 = H 
R2 = H  
37.1 - > 30 
26 
(BMK-21025) 
R1 = H 
R2 = H  
0.0323 0.882 > 20 
27 
(BMK-21028) 
R1 = H 
R2 = CH3 
 
22.9 - > 30 
28 
(BMK-21020) 
R1 = CH3 
R2 = H 
 
0.109 2.23 > 30 
 
Next, inhibitors containing meta-,meta’- (m-,m-) substituted biaryl sulfate as 
a core structure were investigated in the same HCV replication systems (Table 
5). Compound 22, possessing an m-,m’-disubstituted sulfate core and an N-
(methoxycarbonyl)-D-phenylglycine capping group, exhibited extremely high 
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inhibitory activities (EC50 of GT-2a and GT-1b: 0.0199 nM and 0.01983 nM, 
respectively). This is significant since this activity is an approximate 6-fold 
improvement relative to that of the p-,p’-disubstituted biaryl sulfate 17 against 
GT-2a. When the D-phenylglycine capping of compound 22 was replaced with 
L-tert-leucine moiety 23, 4- and 47-fold decreased activity, respectively, 
against GT-1b and GT-2a were surveyed. In the case of inhibitors containing 
an imidazole linker instead of an amide one, compound 24 possessing an N-
(methoxycarbonyl)-D-phenylglycine capping group, proved to be 18- and 503-
fold less potent against GT-1b and GT-2a, respectively, than compound 22. The 
compound 25, which had an L-tert-leucine capping group, showed significantly 
decreased activity (EC50: 37.1 nM) in the GT-1b assay. Notably, compound 26, 
which has an imidazole linker with L-valine capping, showed the highest 
increase in inhibitory activity (132-fold) in the GT-1b assay when compared 
with 21 which has a p-,p’- substituted biaryl sulfate core structure.  
According to our SAR study, the m-,m’-disubstituted biaryl sulfate moiety 
was confirmed to be the best structure for the sulfate core part. Earlier 
observations have suggested that hindered free rotation around the biaryl 
moiety significantly influences the inhibitory activity against NS5A.[53] We 
therefore evaluated whether blocking the free rotation around the sulfate group 
may affect the inhibitory potency. We introduced a methyl substitution at the 
ortho-position of the biaryl groups. Of the compounds containing the m-,m’-
disubstituted aryl sulfate with prolinamide linker, those possessing an o-methyl 
group were first investigated. However, compound 27 and 28, which have 
methyl substitution at the 2- and 2’-positions (compound 27) and 6- and 6’-
positions of the aryl group (compound 28), respectively, showed a significant 
loss in inhibitory activity. For compound 27, the EC50 was 22.9 nM against GT-
1b, and for compound 28, the EC50 was 109 pM against GT-1b and 2.23 nM 
against GT-2a. None of the inhibitors listed in Table 4 and Table 5 were 
cytotoxic at 20 M. 
Table 6. Synthesis and in vitro antiviral activities of inhibitors 
















(R)-Phenyl 0.0100 0.128 
22 
(BMK-21014)  










































(R)-Isopropyl > 1.00c -d 
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aEC50, half-maximal (50%) effective concentration; GT-1b, genotype-1b; 
GT-2a, genotype-2a. 
bAll experiments were performed three times except for compounds that 
exhibited > 1 nM EC50 for GT-1b. 
cExperiment was performed once. 
dNot determined. 
 
The antiviral activities (EC50) of the tested compounds containing amide 
groups on both side of the sulfate core against replicon (GT-1b) and HCVcc 
(GT-2a) are listed in Table 6. We first selected the compounds that exhibited < 
1 nM EC50 for GT-1b, and then measured the HCVcc EC50 for GT-2a. In the 
amide linker series, the D-valine or D-phenylglycine derivatives were chose as 
only capping groups because these groups showed the highest levels of antiviral 
activities in our previous study.[60] 
We first carried out the SAR studies of inhibitors containing a non-symmetric 
sulfate core. The compound 29 containing 3-aminophenyl (4-aminophenyl) 
sulfate derivative equipped with a D-phenylglycine capping moiety showed 36-
fold lower potency against the GT-1b than the symmetric p,p’-substituted 
inhibitor 18 did, while the antiviral activities on GT-2a were reduced by > 6-
fold compared to those of the symmetrically m,m’-substituted biaryl sulfate 
inhibitor 22. The replacement of the D-phenylglycine with D-valine moieties as 
shown in 30 induced no apparent inhibitory activity against GT-1b at 100 nM 
concentration. 
We next investigated the inhibitors containing o-fluoro substituted biaryl 
groups, expecting increased potency based on the restricted rotational 
conformation around the sulfate core. In a previous study, compound 27, which 
was substituted with methyl at 2- and 2’-positions, showed activity at two-digit 
nanomolar levels in GT-1b.[60] However, replacement of the methyl groups of 
compound 27 with fluorine 31 improved the inhibitory activity against GT-1b 
strain with 0.0204 nM EC50. This result, surprisingly, was a 1,127-fold higher 
inhibitory activity than that of compound 27 was, suggesting that the o-position 
in the biaryl groups is extremely important for increasing the potency. 
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The C2 symmetric 6,6’-difluoro-substituted phenol derivatives containing the 
D-phenylglycine moieties 32 also showed increased inhibitory activities against 
both GT-1b and GT-2a, compared to 28, which has o-methyl groups at 6- and 
6’-positions of the biaryl group.[60] Although the inhibitory activities against 
GT-1b were increased, compound 32 showed low GT-2a inhibitory activity 
(single nanomolar level EC50) and compound 31 showed no inhibitory activities 
at 10 nM. 
Nonsymmetrically substituted difluorobiarylsulfate 33 with 2- and 2’-fluoro-
substitution exhibited 5-fold weaker activity for GT-1b and 2-fold higher 
potency for GT-2a compared to symmetric compound 31. The replacement of 
the D-phenylglycine with D-valine moiety (compound 34 and 35) showed lower 
inhibitory activities except for compound 36, which had GT-1b potency to 
single nanomolar range. The fact that the SAR results were highly dependent 
on the substitution and the sulfate linking the position of the biaryl groups 
indicates that the inhibitory activity of various HCV genotype is highly 
sensitive to the structural features of the core moiety. These results indicate that 
ortho-substitution in a phenyl group with fluorine blocks the free rotation, 
which lowers the antiviral activities against GT-1b. Nevertheless, replacing it 
with hydrogen, which lacks steric hindrance relatively, enhanced the inhibitory 





Table 7. Synthesis and in vitro antiviral activities of sulfate core-





































(S)-Isopropyl 0.260 > 10.0c 
aEC50, half-maximal (50%) effective concentration; GT-1b, genotype-1b; 
GT-2a, genotype-2a. 
bAll experiments were performed three times except for compounds that 
exhibited > 1 nM EC50 for GT-1b. 
cExperiment was performed once. 
dNot determined. 
 
As shown in Table 7. we designed the NS5A inhibitor series consisting of 
imidazole linkers with the aim of enhancing the antiviral activities and 
solubility.[64] In our previous report, the imidazole linked biaryl sulfate 
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inhibitors containing an L-valine capping group 26 showed good activities 
against GT-1b and GT-2a.[60] Thus, we introduced nonsymmetric or substituted 
sulfate core structures in imidazole-linked inhibitors to determine if it would 
influence the inhibitory activities and the results are summarized in Table 7. 
Compound 37, containing o-fluoro substituted biaryl sulfate with D-valine 
derivative, showed no inhibitory activity at 100 nM against replicon GT-1b. 
Compound 38 with an N-methoxycarbonyl-L-valine capping group resulted in 
two-digit nM EC50 on GT-1b. The replacement of the L-valine moiety with D-
phenylglycine moiety as in compound 39 dramatically enhanced the antiviral 
activity against GT-1b. However, these results showed 25-fold lower activity 
than that of inhibitors linked with amides such as compound 33. Introduction 
of m-,p’-disubstituted biaryl sulfate core as in compound 40 demonstrated that 
the potencies for both GT-1b and GT-2a were better than that of compound 39 
with an o-fluoro substituent. While the D-valine derivative 41 showed no 
inhibition at 100 nM, the opposite stereoisomeric L-valine derivative 42 showed 
improved potency for GT-1b, respectively. However, it showed no marked 
antiviral activity against GT-2a. 
Based on the SAR study, it can be concluded that compounds with asymmetric 
biaryl sulfate core and D-phenylglycine capping derivatives (compound 29 and 
40) showed the best inhibitory activities for both genotypes. We proceeded to 






Scheme 4. Synthesis of compound 43 (BMK-21060). 
 
 In our previous study, we have found that m,m’-biaryl sulfate derivatives 
exhibit high inhibitory activities against NS5A.[60] Especially, C2-symmetric 
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biaryl sulfate comprising amide 22 and imidazole 26 linkers showed extremely 
high antiviral activities against two genotypes. Based on these results, we 
synthesized compound 43 having a hybridized structure of the two compounds. 
Due to the orthogonality of SuFEx, we were able to synthesize the biaryl sulfate 
compound containing imidazole-proline-L-valine carbamate derivative and 
amide-proline-D-phenylglycine carbamate derivative in moderate yields as 
shown in Scheme 4.[65] The nonsymmetric 43 exhibited excellent inhibitory 
activity for GT-1b. However, it exhibited nanomolar levels of antiviral activity 




Scheme 5. Synthesis of compound 44 (BMK-21057); reagents and 
conditions: (a) TBDMSCl, Imidazole, CH2Cl2, rt, 4 h, 81%; (b) DBU, 
DMF, 50 ℃, 12 h, 75%; (c) TFA, CH2Cl2, rt, 30 m; (d) EDCI, HOBt, 




We also used SuFEx chemistry to prepare the biotin-tagged, biaryl sulfate core 
based NS5A inhibitor as shown in Scheme 5. Biotin binds specific proteins 
such as streptavidin and avidin with extremely high affinity.[20] Because of this 
specificity, biotinylation of NS5A inhibitors has been reported.[66] The 
introduction of biotin into one proline was readily carried out using SuFex 
chemistry. Although the NS5A inhibitor containing the biaryl sulfate with 
biotin-tag 44 showed a slightly decreased EC50 against genotype-1b (9.59 nM), 
it was 10 times higher than the previously reported biotinylated tag molecules 
based on BMS compound (BMS-671 and BMS-690).[20, 31, 66] 
 
 
Figure 5. Docking of inhibitor compounds to an NS5A (3FQQ) dimer 
model. (A) compound 18, (B) compound 22, and (C) compound 29 to an 
NS5A (3FQQ) dimer model. For clarity purpose, only residues having 
interactions were shown. Compound 18, 22, and 29 are shown in stick 
and surrounding residues were shown in line. Various interactions are 
shown in dashes (for more clarity see Figure 11). (D) Superposed model 
of inhibitors inside 3FQQ dimer model. Compound 18, 22, and 29 are 






To understand the observed antiviral activities (EC50) of inhibitors from a 3D 
structural perspective, three representative inhibitors, compound 18, 22, and 
29, were docked in an NS5A protein dimer model. The model was constructed 
using the NS5A domain 1 crystal structure (3FQQ)[22] and amino terminal alpha 
helical NMR structure (1R7G).[67] Figure 5 illustrates the 3D-interaction models 
of compound 18, 22, and 29 with the NS5A dimer. The docking model 
demonstrates that inhibitors bound across the dimer interface with Thr95A, 
which forms a hydrogen bond with the nonsymmetric biaryl sulfate core. The 
interactions of inhibitors and the residues at the binding site are detailed in two 
dimensional (2D) docking representation (Figure 11). In the case of compound 
18, the biaryl sulfate moiety can engage in hydrophobic interaction with 
Gln54A and Gln54B, whereas the methyl groups of the carbamate groups make 
π-alkyl interaction with Pro58 and Tyr93 of the NS5A protein dimer (Figure 
5A and Figure 11A). The amide linkers of compound 22 make hydrogen bond 
with Gln54, Thr56, and Gln62, whereas both methyl groups of the carbamates 
involve π-alkyl interaction with Pro58 and Tyr93 (Figure 5B and Figure 11B). 
In compound 29 (Figure 5C), the sulfate moiety appears to interact with Thr95 
by hydrogen bonding. Interestingly, Tyr93A has π-alkyl interaction with the 
pyrrolidine ring and the methyl moiety of methyl carbamate, whereas Tyr93B 
shows π-donor hydrogen bond interaction with the phenyl group of D-
phenylglycine. There are no interactions with the residues of Pro58 (Figure 
11C). 
 As shown in a superposed model (Figure 5D and Figure 11A-B), the 
symmetric inhibitors 18 and 22 pose reduced steric hindrance of D-
phenylglycine moiety compared to nonsymmetrical inhibitor 29, where only 
one methyl group of the carbamates is involved in π-alkyl interaction with 
Tyr93A. Also, CDocker interaction energies of compound 18, 22, and 29 are 
−58.41, −57.20, and −46.19 kcal/mol, respectively, which suggests that 
compound 18 and 22 might be better placed in the binding mode compared to 
29. In the case of inhibitor 40, hydrogen bond interactions are found not only 
between the sulfate and Gly54A but also between the imidazole and Thr56 
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(Figure 11D). Both ends of the carbamate groups appear to show π-alkyl 
interaction with Tyr93A and Tyr93B, and especially Tyr93A is engaged in 
hydrogen bond interaction with the carbonyl moiety of one carbamate. 
Interestingly, one methyl group of the carbamate makes hydrophobic 
interaction with Pro58B, whereas the other side correlates with Pro97B. 
Therefore, the D-phenylglycine of inhibitor 40 poses reduced steric hindrance 
compared to inhibitor 29 due to the hydrogen bonding of the carbamate group 
(Figure 13). CDocker interaction energy of inhibitor 40 is −54.76 kcal/mol, 
which bodes well with its EC50 activity. 
 
Table 8. Results of hERG ligand binding assay.a 
Treatment Concentration (M) % inhibition 
22 
(BMK-21014) 
10 2.73 ± 3.16 
26 
(BMK-21025) 
10 18.7 ± 4.58 
Astemizole 
(positive control) 
10 66.0 ± 5.22 
amean ± SD, n=3 
 
Based on these results, we evaluated the top two compounds, 22 and 26, which 
contain the amide and imidazole linker, respectively, in a battery of 
pharmacological studies. First, we assessed the hERG ligand binding of 
compounds 22 and 26 at 10 M (Table 8). The hERG ligand binding assay is 
used for the evaluation of potential heart related safety issues.[33, 68] By using 
“red fluorescent hERG channel ligand tracer”, the inhibition potential of test 
compounds could be evaluated.[54] In the case of hERG inhibiting chemicals, 
the tracers do not bind to the membrane resulting in low polarization.[33, 55] 
The % inhibition values of compounds on hERG ligand binding are listed in 
Table 8. Compounds having inhibition value more than 50% of the positive 
control such as astemizole are considered to possess potential cardiotoxicity.[69] 
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However, compounds 22 and 26 showed no significant inhibition potential in 
this study.  
 
Table 9. Plasma stability.a 
Treatment Rat (%) Human (%) 
22 
(BMK-21014) 
76.7 ± 10.6 86.3 ± 12.3 
26 
(BMK-21025) 
87.2 ± 12.6 92.6 ± 9.69 
Enalapril  
(Positive control) 
0.032 ± 0.003 - 
Procaine  
(Positive control) 
- 0.003 ± 0.002 
a% remaining after 4 h incubation at 37°C 
 
Next, we measured the stabilities of compounds 22 and 26 against hydrolytic 
enzymes, such as aldolase, cholinesterase, acid phosphatase, alkaline, 
dehydropeptidase and lipase in rat and human plasma (Table 9). Because the 
hydrolysis of candidate molecules in plasma can result in low stability, it is 
important to assess liability of test compounds.[13, 70] When compounds 22 and 
26 were tested, results showed high stability in rat and human plasma when 











Revertant colonies/plate (Mean ± SD)b 
Without S-9 mix With S-9 mix 
TA98 
vehicle control 0 21 ± 1 25 ± 3 
22 
(BMK-21014) 
1,000 26 ± 3 29 ± 2 
26 
(BMK-21025) 




1 ± 1 
(vehicle  
control: 1 ± 1) 
1 ± 1 
(vehicle  
control: 1 ± 1) 
TA100 
vehicle control 0 125 ± 9 129 ± 3 
22 
(BMK-21014) 
1,000 126 ± 7 130 ± 9 
26 
(BMK-21025) 




10 ± 7 
(vehicle  
control: 7 ± 2) 
8 ± 1 
(vehicle  
control: 5 ± 2) 
 Positive control Dose Without S-9 mix With S-9 mix 
TA98 
2-nitrofluorene 1 μg/plate 183 ± 24 ND 
Benzo(a)pyrene 2 μg/plate NDa 198 ± 15 
TA100 
Sodium azide 1 748 ± 25 ND 
Benzo(a)pyrene 2 ND 778 ± 14 
aND: Non Determined. 
bMean ± SD, n=3 
 
We then proceeded to evaluate the two compounds for genotoxicity in the 
Ames test (Table 10). We chose the commonly used Salmonella typhimurium 
strains TA98 and TA100 for the detection of frameshift mutations and base 
substitution mutations, respectively.[61] In this study, the positive controls 
increased the amount of revertant colonies significantly in TA98 and TA100.[12, 
62]  There was no increase in the quantity of revertant colonies observed when 
compounds 22 or 26 (1,000 g/plate) were applied. In other words, neither test 
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compound had mutagenic potential against TA98 and TA100. In addition, the 
evaluation of bis(4-aminophenyl) sulfate, which is a potential metabolite of 
compound 22, in the Ames MPF™ 98/100 Mutagenicity Assay showed no 










ED50 ED75 ED90 ED95 
BMK-21014 + 
sofosbuvir 
0.87160 0.90939 0.94888 0.97676 
BMK-21025 + 
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To evaluate compounds 22 and 26 in combination with a representative 
NS5B inhibitor, sofosbuvir, we adopted the Chou method.[71-73] Compound 22 
or 26 was tested at a constant ratio of sofosbuvir to NK5.1 Gluc replicon and, 
each inhibition effect was measured through the Gaussia luciferase assay. We 
calculated the relative inhibition effect of cells treated with single or 
combination administrations compared with mock treated replicon cells (Figure 
6). To evaluate the combination index (CI) values, such as effective dose (ED) 
at each point (ED50, ED75, ED90, and ED95), we used the Compusyn Freeware 
Program (ComboSyn, Inc). Compound 22 showed CI values below 1 at 50%, 
75%, 90%, and 95% ED concentrations. On the other hand, compound 26 
exhibited CI values almost similar to 1 in ED50 and ED75, and above 1 in ED90 
and ED95. In conclusion, we suggest that compound 22 has a synergic effect 
with sofosbuvir, but that compound 26 shows a dose-dependent additive effect 




In summary, we investigated new compounds containing biaryl sulfone or 
sulfate cores as inhibitors of the hepatitis C virus NS5A protein. Especially,  
using SuFEx chemistry we achieved chemoselective coupling of aryl 
fluorosulfates and aryl silyl ethers in the presence of a catalytic amount of a 
DBU as a base. Furthermore, this method was used to synthesize new NS5A 
inhibitors containing various substituted sulfate core structures with high yields. 
These compounds exhibited high inhibitory activities against HCV viral 
proliferation by binding NS5A protein. We easily synthesized inhibitors 
containing nonsymmertric or o-fluoro substituted biaryl sulfate core structures 
using the SuFEx reaction in a “click chemistry” manner. Based on these results, 
SuFEx chemistry proved to be highly useful in constructing symmetric and 
nonsymmetric sulfate core-containing NS5A inhibitors, and could potentially 
be applied to the synthesis of a wider range of compounds in medicinal 
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chemistry. Through SAR study, we discovered that two compounds containing 
an m-,m’-disubstituted biaryl sulfate core, 22 or 26, exhibit excellent inhibitory 
potencies against both GT-1b and GT-2a. In hERG ligand binding inhibition 
assays, no inhibition activity was detected for either 22 or 26. These compounds 
showed high plasma stability and no mutagenic potential as evaluated by the 
Ames test. In addition, compounds 22 or 26 had synergistic or nearly additive 
combination effect with sofosbuvir, respectively. Based on these encouraging 




General chemical methods 
The 1H and 13C NMR-spectra were measured with a Varian/Oxford As-500 
(500 MHz), and an Agilent 400-MR DD2 Magnetic Resonance System (400 
MHz) spectrophotometer. Chemical shifts were measured as part per million (δ 
values) from Tetramethylsilane (TMS) as an internal standard at probe 
temperature in CD3OD or CDCl3 or DMSO-D6 for neutral compounds. 
Coupling constants are provided in Hz, with the following spectral pattern 
designations: s, singlet; d, doublet; t, triplet; q, quartet; quint, quintet; m, 
multiplet; br, broad; app, apparent. Reactions were conducted, purified, and 
analyzed according to methods widely practiced in the field, while taking 
necessary precautions in the exclusion of moisture and/or oxygen where 
appropriate. Evaporation of solvents was performed at reduced pressure using 
a rotary evaporator. TLC was performed using silica gel 60F254 coated on an 
aluminum sheet (E. Merck, Art.5554). High resolution mass spectra (HRMS) 
were recorded on a ThermoFinnigan LCQ™ Classic, Quadrupole Ion-Trap 
Mass Spectrometer. HPLC analyses were carried out on an Agilent HP1100 
system (Santa Clara, CA, USA), composed of an auto sampler, quaternary 
pump, photodiode array detector (DAD), and HP Chemstation software. The 
separation was carried out on a poroshell 120 EC-C18 column 50 X 4.6 mm, 
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2.7 m with acetonitrile (A), 0.1% TFA in water (B), as a mobile phase at a 
flow rate of 1 mL/min at 20℃. Method: 5% A and 95% B (0 min), 50% A and 
50% B (15 min), 95% A and 5% B (24min), 95% A and 5% B (25min), 5% A 
and 95% B (26 min), 5% A and 95% B (27 min). All materials were purchased 
from a commercial supplier and used without further purification unless 
otherwise noted. 
 
(Methoxycarbonyl)-D-valine (Cap-1). Na2CO3 (276 mg, 2.6 mmol) was added 
to aq NaOH (5 mL of 1 M/H2O, 5 mmol) solution of D-valine (586 mg, 5.00 
mmol) and the resulting solution was cooled with ice-water bath. Methyl 
chloroformate (0.420 mL, 5.40 mmol) was added dropwise, the cooling bath 
was removed and the reaction mixture was stirred at ambient temperature for 
3.25 h. The reaction mixture was washed with ether (3x9 mL), and the aqueous 
phase was cooled with ice-water bath and acidified with conc HCl to a pH 
region of 1-2, and extracted with CH2Cl2 (3x9 mL). The organic phase was 
dried (MgSO4), filtered, and concentrated in vacuo to afford Cap-1 as a white 
solid (760 mg, 87%). 1H NMR (DMSO-d6, δ=2.5 ppm, 300 MHz): 12.54 (s, 
1H), 7.32 (d, 1H), 3.84 (t, 1H), 3.54 (s, 3H), 2.03 (m, 1H), 0.87 (d, 6H). 
 
(Methoxycarbonyl)-L-valine (Cap-2). Yield 5.0 g (86%); 1H NMR (DMSO-d6, 
δ=2.5 ppm, 400 MHz): 12.51 (br s, 1H), 7.32 (d, 1H), 3.84 (t, 1H), 3.54 (s, 3H), 
2.03 (m, 1H), 0.88 (d, J=12, 6H). 
 
(R)-2-((methoxycarbonyl)amino)-2-phenylacetic acid (Cap-3). Yield 1.4 g 
(67%); 1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): 12.79 (br s, 1H), 7.96 (d, 
J=12, 1H), 7.40-7.29 (m, 5H), 5.13 (d, J=12, 1H), 3.55 (s, 3H). 
 
(S)-2-((methoxycarbonyl)amino)-3,3-dimethylbutanoic acid (Cap-4). Yield 
670 mg (71%); 1H NMR (CDCl3, δ=7.26 ppm, 500 MHz): 9.57 (br s, 1H), 5.31 





bonyl))(2S,2'S)-bis(pyrrolidine-1-carboxylate) (2). A mixture of 4,4'-
Diaminodiphenyl Sulfone 1 (481 mg, 1.94 mmol), N-Boc-L-proline (1.00 g, 
4.65 mmol), and EDCI (945 mg, 5.03 mmol) in CH2Cl2 (10 mL) was stirred at 
room temperature for 16 h. The mixture was then poured in 1 N aq. HCl solution 
and extracted with CH2Cl2. The organic layer dried over magnesium sulfate, 
filtered, and concentrated in vacuo. Then without any purification, tert-Butyl 
(S)-2-((4-((4-((R)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxamido)phenyl)-
sulfonyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate 2 was obtained as white 
solid (544 mg, 44%). 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 10.43 (s, 
2H), 7.89-7.79 (m, 8H), 4.27-4.18 (m, 2H), 3.44-3.39 (m, 4H), 2.19-2.16 (m, 
2H), 1.99-1.78 (m, 6H), 1.38-1.23 (app br s, 18H). 13C NMR (DMSO-d6, 
δ=39.52 ppm, 100 MHz): 172.3, 153.0, 143.4, 135.3, 128.5, 119.2, 113.0, 78.6, 
62.8, 60.4, 46.5, 45.1, 33.1, 30.9, 30.1, 27.9, 26.7, 26.6, 24.0, 23.4, 13.1. HRMS 





diyl))dicarbamate (13, BMK-21006). Yield 111 mg (50 %); 1H NMR (DMSO-
d6, δ=2.5 ppm, 400 MHz): 10.37 (s, 2H), 7.87-7.85 (d, 4H), 7.82-7.80 (d, 4H), 
7.73-7.57 (q, 2H), 7.40-7.29 (m, 9H), 7.20-6.99 (q, 1H), 5.50-5.48 (d, 2H), 
4.38-4.37 (d, 2H), 3.80-3.70 (m, 2H), 3.52 (s, 6H), 3.20-3.14 (q, 2H), 2.02-1.94 
(m, 4H), 1.91-1.78 (m, 4H). 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): 
171.0, 168.3, 156.0, 143.4, 137.2, 135.3, 128.6, 128.0, 119.2, 60.7, 56.6, 51.6, 
46.9, 29.2, 24.3. HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ C42H44N6NaO10S: 




diyl))dicarbamate (14, BMK-21056). Yield 65.8 mg (53 %); 1H NMR (DMSO-
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d6, δ=2.5 ppm, 400 MHz): 10.49 (s, 2H), 7.85-7.76 (m, 8H), 7.33-7.32 (d, 2H), 
4.43 (s, 2H), 4.04-4.02 (t, 2H), 3.80 (s, 2H), 3.61 (s, 2H), 3.52 (s, 6H), 2.16 (s, 
2H), 1.96-1.87 (m, 8H), 0.93-0.87 (m, 12H). 13C NMR (DMSO-d6, δ=39.52 
ppm, 100 MHz): 171.2, 170.4, 156.8, 143.5, 135.2, 128.4, 119.0, 60.3, 57.9, 
51.5, 51.4, 47.2, 29.8, 29.3, 24.7, 18.9, 18.6. HRMS (ESI) m/z: Anal. calcd. for 




diyl))dicarbamate (15, BMK-21033). Yield 53.1 mg (55 %); 1H NMR (DMSO-
d6, δ=2.5 ppm, 500 MHz): 10.72-10.24 (app s, 2H), 7.99-7.84 (m, 4H), 7.82-
7.71 (m, 4H), 7.56-7.33 (m, 2H), 4.41-4.40 (d, 2H), 4.10-4.07 (t, 2H), 3.78-3.68 
(m, 2H), 3.63-3.59 (m, 1H), 3.54 (s, 6H), 3.46-3.44 (t, 1H), 2.18-2.09 (m, 2H), 
2.04-1.82 (m, 8H), 0.88-0.85 (t, 10H), 0.77-0.76 (d, 1H), 0.68-0.67 (d, 1H). 13C 
NMR (DMSO-d6, δ=39.52 ppm, 125 MHz): 171.2, 170.2, 156.9, 143.3, 135.3, 
128.4, 119.1, 60.3, 57.9, 51.6, 47.7, 29.7, 29.3, 24.3, 19.1, 18.3. HRMS (ESI) 
m/z: Anal. calcd. for [M+Na]+ C36H48N6NaO10S: 779.3045; found 779.3045. 
 
General procedure for synthesis of aminophenol 
A stirred mixture of Nitro phenol (12.7 mmol) in MeOH (50 mL) at 
room temperature was treated with 10 wt% palladium on charcoal (100 
mg). Hydrogen gas was passed through the mixture for 24 h, and then the 
palladium on charcoal was removed by filtration through Celite. The 
filtrate was concentrated in vacuo, and was obtained as solid product. 
 
3-Amino-2-methylphenol (4a). Yield (1.62 g, 99%); 1H NMR (CD3OD, δ=3.31 
ppm, 400 MHz): 6.77-6.73, (t, 1H), 6.29-6.27 (d, 1H), 6.22-6.20 (d, 1H), 2.02 
(s, 3H). 13C NMR (CD3OD, δ=49.00 ppm, 100 MHz): 156.7, 147.5, 127.2, 
110.9, 108.8, 106.7, 9.2. HRMS (ESI) m/z: Anal. calcd. for [M+H]+ C7H10NO: 




3-Amino-2-fluorophenol (4b). Yield (1.65 g, 99%); 1H NMR (CD3OD, 
δ=3.31 ppm, 400 MHz): δ 6.69-6.65 (t, 1H), 6.34-6.25 (m, 2H); 13C NMR 
(CD3OD, δ=49.00 ppm, 100 MHz): δ 146.13, 143.90, 141.59, 124.71, 
109.49, 107.95; 19F NMR (CD3OD, 376 MHz): δ -161.96; HRMS (ESI) 
m/z: Anal. calcd. for [M+H]+ C6H7FNO: 128.0506; found 128.0482. 
 
5-Amino-2-fluorophenol (4c). Yield (809 mg, 99%); 1H NMR (CD3OD, 
δ=3.31 ppm, 400 MHz): δ 6.78-6.73, (t, 1H), 6.34-6.31 (q, 1H), 6.17-6.13 
(m, 1H); 13C NMR (CD3OD, δ=49.00 ppm, 100 MHz): δ 147.94, 145.65, 
145.15, 116.60, 107.67, 106.22; 19F NMR (CD3OD, 376 MHz): δ -152.91; 
HRMS (ESI) m/z: Anal. calcd. for [M+H]+ C6H7FNO: 128.0506; found 
128.0508. 
 
General procedure for synthesis of amide linked intermediate 
A mixture of Amino phenol (12.6 mmol), N-Boc-L-proline (3.25 g, 
15.1 mmol), and EDCI (2.11 g, 16.4 mmol) in CH2Cl2 (30 mL) was stirred 
at room temperature for 4 h. The mixture was then poured in 1 N aq HCl 
solution and Extracted with CH2Cl2. The organic layer dried over 
magnesium sulfate, and then was purified by the column chromatography 
(n-hexane / ethyl acetate). The residue was obtained as solid product. 
 
tert-Butyl (S)-2-((3-hydroxy-2-methylphenyl)carbamoyl)pyrrolidine-1-
carboxylate (5a). Yield (1.76 g, 99%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 
MHz): 9.36-9.24 (t, 2H), 6.94 (s, 1H), 6.82-6.78 (d, 1H), 6.65 (s, 1H), 4.29 (s, 
1H), 3.42-3.32 (m, 2H), 2.23-2.14 (d, 1H), 1.99 (s, 3H), 1.89-1.81 (m, 3H), 
1.42-1.37 (app br s, 9H). 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): 171.3, 
155.7, 153.3, 137.1, 125.5, 119.3, 116.2, 111.8, 78.5, 60.0, 46.6, 31.4, 28.1, 23.3, 






carboxylate (5b). Yield 1.92 g (74%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 
MHz): 9.73 (s, 1H), 9.27 (s, 1H), 7.21 (s, 1H), 6.94-6.92 (d, 1H), 6.86-6.84 (d, 
1H), 4.23-4.13 (m, 1H), 3.39 (s, 2H), 2.20-2.17 (d, 1H), 2.04 (s, 3H), 1.86-1.80 
(m, 3H), 1.39-1.23 (app br s, 9H). 13C NMR (DMSO-d6, δ=39.52 ppm, 100 
MHz): 171.1, 155.2, 153.2, 137.6, 130.2, 118.6, 109.9, 106.2, 78.4, 60.3, 46.5, 
31.0, 28.0, 23.4, 15.5. HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ 
C17H24N2NaO4: 343.1628; found 343.1626. 
 
tert-Butyl (S)-2-((3-hydroxyphenyl)carbamoyl)pyrrolidine-1-carboxylate (5c). 
Yield 5.41 g (96%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 9.83 (s, 1H), 
9.36 (s, 1H), 7.18 (s, 1H), 7.08-7.04 (t, 1H), 6.96-6.94 (d, 1H), 6.45-6.43 (d, 
1H), 4.24-4.15 (m, 1H), 3.37 (m, 1H), 3.33-3.32 (m, 1H), 2.17-2.08 (m, 1H), 
1.86-1.75 (m, 3H), 1.39-1.27 (app br s, 9H). 13C NMR (DMSO-d6, δ=39.52 
ppm, 100 MHz): 171.4, 157.6, 153.2, 140.2, 129.3, 110.4, 110.1, 106.6, 78.5, 
60.4, 46.6, 31.1, 28.0, 23.4. HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ 
C16H22N2NaO4: 329.1472; found 329.1474. 
 
tert-Butyl (S)-2-((4-hydroxyphenyl)carbamoyl)pyrrolidine-1-carboxylate 
(5d). Yield 5.36 g (87%). 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 9.68 (s, 
1H), 9.16 (s, 1H), 7.37-7.34 (d, 2H), 6.70-6.67 (d, 2H), 4.22-4.12 (m, 1H), 3.43-
3.37 (m, 1H), 3.35-3.29 (m, 1H), 2.19-2.12 (m, 1H), 1.91-1.74 (m, 3H), 1.39-
1.28 (app br s, 9H). 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): 170.8, 
153.3, 130.7, 121.0, 115.0, 78.4, 60.3, 46.6, 31.0, 30.2, 28.0, 24.0, 23.4. HRMS 
(ESI) m/z: Anal. calcd. for [M+Na]+ C16H22N2NaO4: 329.1472; found 329.1472. 
tert-Butyl (S)-2-((2-fluoro-3-hydroxyphenyl)carbamoyl)-pyrrolidine-1-
carboxylate (5e). Yield (3.79 g, 93%); 1H NMR (DMSO-d6, δ=2.5 ppm, 
500 MHz): δ 9.84 (s, 1H), 9.63 (s, 1H), 7.32-7.21 (m, 1H), 6.90-6.89 (d, 
1H), 6.71-6.70 (d, 1H), 4.42-4.33 (m, 1H), 3.40 (s, 1H), 3.36-3.32 (m, 
1H), 2.20-2.12 (m, 1H), 1.87-1.78 (m, 3H), 1.40-1.31 (app br s, 9H); 13C 
NMR (DMSO-d6, δ=39.52 ppm, 126 MHz): δ 171.90, 153.34, 145.34, 
52 
 
142.79, 127.08, 123.46, 114.31, 113.46, 78.66, 60.03, 46.67, 31.23, 28.02, 
23.43; 19F NMR (DMSO-d6, 376 MHz): δ -147.91, -149.01; HRMS (ESI) 




carboxylate (5f). Yield (748 mg, 59%); 1H NMR (DMSO-d6, δ=2.5 ppm, 
400 MHz): δ 9.83 (s, 2H), 7.38-7.36 (d, 1H), 7.05-7.00 (t, 1H), 6.95-6.91 
(m, 1H), 4.23- 4.13 (m, 1H), 3.44-3.38 (m, 1H), 3.35-3.32 (m, 1H), 2.23-
2.12 (m, 1H), 1.91-1.75 (m, 3H), 1.39-1.28 (app br s, 9H); 13C NMR 
(DMSO-d6, δ=39.52 ppm, 100 MHz): δ 171.19, 153.11, 148.05, 146.15, 
144.59, 135.46, 115.49, 109.99, 109.09, 78.40, 60.30, 46.49, 30.92, 30.09, 
28.09, 27.89, 23.87, 23.29; 19F NMR (DMSO-d6, 376 MHz): δ -141.97; 
HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ C16H21FN2NaO4: 347.1378; 
found 347.1379. 
 
2-Bromo-1-(4-fluoro-3-hydroxyphenyl)ethan-1-one (7a). A mixture of 
4-Fluoro-3-hydroxyacetophenone (100 mg, 0.649 mmol), copper (II) 
bromide (174 mg, 0.779 mmol) in Ethyl acetate (5 mL) / Chloroform (5 
mL) was heated and refluxed for 8 h. The mixture was then filtered to 
remove the copper (I) bromide. The filtrate was concentrated in vacuo, 
and was obtained as yellow solid (123 mg, 81%); 1H NMR (CDCl3, 
δ=7.26 ppm, 400 MHz): δ 7.67-7.64 (m, 1H), 7.56-7.51 (m, 1H), 7.19-
7.13 (m, 1H), 5.63 (s, 1H), 4.38 (s, 2H); 13C NMR (CDCl3, δ=77.16 ppm, 
100 MHz): δ 190.18, 155.97, 153.50, 144.29, 131.19, 122.62, 118.44, 
116.35, 30.63; 19F NMR (CDCl3, 376 MHz): -130.70; HRMS (ESI) m/z: 
Anal. calcd. for [M+Na]+ C8H6BrFNaO2: 254.9427; found 254.9428. 
 
General procedure for synthesis of keto ester derivatives 
2-Bromo-acetophenone (0.416 mmol) and N-Boc-L-proline (0.499 mmol) 
in Acetonitrile (10 mL) put into the flask. Diisopropylethylamine (0.541 
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mmol) was added dropwise to the mixture and was stirred at room 
temperature for 5 h. The mixture was then poured in 1 N aq HCl solution 
and extracted with CH2Cl2. The organic layer dried over magnesium 
sulfate, and then was purified by the column chromatography (n-hexane 
/ ethyl acetate). The residue was obtained as white solid. 
 
1-(tert-Butyl) 2-(2-(4-fluoro-3-hydroxyphenyl)-2-oxoethyl) (S)-
pyrrolidine-1,2-dicarboxylate (8a). Yield (110 mg, 72%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400 MHz): δ 10.43 (s, 1H), 7.55-7.48 (m, 2H), 
7.34-7.29 (m, 1H), 5.56-5.36 (m, 2H), 4.35-4.39/4.08-4.03 (2 m, 
0.86H+0.28H), 3.41-3.34 (m, 1H), 3.28-3.16 (m, 1H), 2.32-2.09 (m, 1H), 
1.92-1.76 (m, 3H), 1.36 (app br s, 9H); 13C NMR (DMSO-d6, δ=39.52 
ppm, 100 MHz): δ 191.37, 172.33, 155.97, 153.00, 145.44, 130.79, 
120.36, 116.90, 116.55, 79.06, 66.41, 58.56, 46.22, 30.47, 29.55, 27.96, 
23.88, 23.12; 19F NMR (DMSO-d6, 376 MHz): δ -127.51; HRMS (ESI) 




dicarboxylate (8b). Yield (1.20 g, 74%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 
MHz): 10.49 (s, 1H), 7.86-7.85 (d, 2H), 6.88-6.86 (t, 2H), 5.53-5.32 (m, 2H), 
4.32-4.29 (m, 1H), 3.11 (m, 2H), 2.29-2.14 (m, 2H), 1.90-1.85 (m, 2H), 1.36 
(app br s, 9H). 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): 190.5, 172.3, 
162.7, 153.0, 130.4, 125.4, 115.4, 78.9, 66.1, 58.6, 46.2, 30.4, 27.9, 23.1. 




dicarboxylate (8c). Yield 1.47 g (91%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 
MHz): 9.88 (s, 1H), 7.45-7.43 (d, 1H), 7.37-7.33 (m, 2H), 7.10-7.08 (d, 1H), 
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5.58-5.38 (m, 2H), 4.37-4.31 (m, 1H), 3.41-3.31 (m, 2H), 2.34-2.10 (m, 2H), 
1.92-1.82 (m, 2H), 1.40-1.37 (app br s, 9H).13C NMR (DMSO-d6, δ=39.52 ppm, 
100 MHz): 192.4, 172.3, 157.8, 153.0, 135.2, 130.0, 121.1, 118.7, 113.9, 79.0, 
66.6, 58.6, 46.2, 30.5, 29.6, 28.1, 27.9, 23.9, 23.1. HRMS (ESI) m/z: Anal. calcd. 
for [M+Na]+ C18H23NNaO6: 372.1418; found 372.1417. 
 
General procedure for synthesis of imidazole linked 
intermediate 
A mixture of keto ester (0.554 mmol) and Ammonium acetate (8.30 
mmol) were suspended in Toluene (10 mL). The reaction mixture was 
heated to 90 °C and stirred for 20 h. The mixture was then poured in H2O 
and extracted with ethyl acetate. The organic layer dried over magnesium 
sulfate and evaporated in vacuo. After evaporation, the residue was 
purified by the column chromatography (n-hexane / ethyl acetate). Then 
product was obtained as yellow solid. 
 
tert-Butyl (S)-2-(5-(4-fluoro-3-hydroxyphenyl)-1H-imidazol-2-
yl)pyrrolidine-1-carboxylate (9a). yield (101 mg, 52%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400 MHz): δ 12.06/11.83-11.76 (s/d, 
0.16H+0.76H), 9.70 (s, 1H), 7.35 (s, 2H), 7.10-7.01 (m, 2H), 4.80-4.73 
(d, 1H), 3.52 (s, 1H), 2.32-2.15 (m, 1H), 1.97-1.76 (m, 4H), 1.39-1.15 
(app br s, 9H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): δ 153.39, 
150.76, 144.58, 138.79, 131.95, 115.97, 115.18, 113.60, 111.31, 78.60, 
58.75, 55.20, 46.28, 33.32, 27.88, 23.88, 23.14; 19F NMR (DMSO-d6, 376 
MHz): δ -138.76, -140.30; HRMS (ESI) m/z: Anal. calcd. for [M+H]+ 
C18H23FN3O3: 348.1718; found 348.1719. 
 
tert-Butyl (S)-2-(5-(4-hydroxyphenyl)-1H-imidazol-2-yl)-pyrrolidine-1-
carboxylate (9b). Yield (887 mg, 47%); 1H NMR (DMSO-d6, δ=2.5 ppm, 
400 MHz): δ 11.76 (br s, 1H), 9.48 (br s, 1H), 7.53 (s, 2H), 7.20 (s, 1H), 
6.77-6.75 (d, 2H), 4.83-4.76 (d, 1H), 3.54-3.35 (d, 2H), 2.20-1.81 (m, 4H), 
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1.39-1.17 (app br s, 9H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): 
δ 155.93, 153.82, 153.47, 150.09, 125.54, 115.30, 78.23, 55.26, 46.34, 
33.41, 31.88, 27.93, 23.85, 23.16; HRMS (ESI) m/z: Anal. calcd. for 
[M+Na]+ C18H23N3NaO3: 352.1632; found 352.1634. 
 
tert-Butyl (S)-2-(5-(3-hydroxyphenyl)-1H-imidazol-2-yl)-pyrrolidine-1-
carboxylate (9c). Yield (456 mg, 45%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 
MHz): δ 11.88 (br s, 1H), 9.41 (br s, 1H), 7.34-7.11 (m, 4H), 6.60 (s, 1H), 4.85-
4.77 (d, 1H), 3.55 (s, 1H), 3.35 (s, 1H), 2.22-2.14 (m, 1H), 1.99-1.82 (m, 3H), 
1.39-1.16 (app br s, 9H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): δ 
157.66, 153.51, 129.43, 115.25, 113.14, 111.25, 78.32, 55.33, 48.72, 46.42, 
33.49, 31.93, 27.96, 23.93, 23.25; HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ 
C18H23N3NaO3: 352.1632; found 352.1634. 
 
General procedure for synthesis of fosylated intermediate 
A mixture of phenol derivative (0.800 mmol) and N,N-
Diisopropylethylamine (1.20 mmol) in CH2Cl2 (5 mL) was stirred under 
sulfuryl fluoride at room temperature for 5 h. The mixture was then 
poured in 1 N aq HCl solution and extracted with CH2Cl2. The organic 
layer dried over magnesium sulfate, filtered, and concentrated in vacuo. 
Without any purification, the residue was obtained as an oil. 
 
tert-Butyl (S)-2-((4-((fluorosulfonyl)oxy)phenyl)carbamoyl)-pyrrolidine-1-
carboxylate (10a). Yield (278 mg, 90%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 
MHz): δ 10.31 (s, 1H), 7.82-7.80 (d, 2H), 7.53-7.51 (d, 2H), 4.28-4.21 (m, 1H), 
3.42 (s, 2H), 2.21 (s, 1H), 1.89-1.79 (m, 3H), 1.38-1.27 (app s, 9H); 13C NMR 
(DMSO-d6, δ=39.52 ppm, 100 MHz): δ 171.97, 153.13, 144.74, 139.67, 121.53, 
120.75, 78.57, 60.46, 46.58, 31.01, 30.16, 27.92, 23.99, 23.39; 19F NMR 
(CD3OD, 376 MHz,): 31.23; HRMS (ESI) m/z: Anal. calcd. for [M+Na]
+ 





lidine-1-carboxylate (10b). Yield (1.66 g, 87%); 1H NMR (DMSO-d6, 
δ=2.5 ppm, 400 MHz): δ 10.43-10.41 (d, 1H), 7.98 (s, 1H), 7.62-7.59 (t, 
1H), 7.55-7.50 (m, 1H), 7.26-7.24 (d, 1H), 4.27-4.17 (m, 1H), 3.46-3.40 
(m, 1H), 3.37-3.31 (m, 1H), 2.24-2.16 (m, 1H), 1.94-1.77 (m, 3H), 1.39-
1.25 (app s, 9H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): δ 
172.23, 153.06, 149.63, 141.01, 131.00, 119.33, 115.30, 111.07, 78.61, 
60.48, 46.57, 30.91, 30.11, 27.87, 23.98, 23.39; 19F NMR (CD3OD, 376 
MHz,): 38.49; HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ 
C16H21FN2NaO6S: 411.0997; found 411.0998. 
 
tert-Butyl (S)-2-((2-fluoro-3-((fluorosulfonyl)oxy)phenyl)-carbamoyl)-
pyrrolidine-1-carboxylate (10c). Yield (364 mg, 83%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400 MHz): δ 10.18 (s, 1H), 8.04-7.95 (d, 1H), 
7.54 (s, 1H), 7.39-7.35 (t, 1H), 4.45-4.36 (m, 1H), 3.42 (s, 1H), 3.37-3.33 
(m, 1H), 2.23-2.16 (m, 1H), 1.92-1.80 (s, 3H), 1.40-1.31 (app s, 9H); 13C 
NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): δ 172.20, 153.08, 146.52, 
144.00, 136.75, 128.31, 124.97, 118.45, 78.61, 59.87, 46.55, 31.04, 29.94, 
27.86, 23.94, 23.30; 19F NMR (DMSO-d6, 376 MHz): δ 39.69, -139.30, -
140.16; HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ C16H20F2N2NaO6S: 
429.0902; found 429.0902. 
 
tert-Butyl (S)-2-((4-fluoro-3-((fluorosulfonyl)oxy)phenyl)carbamoyl)-
pyrrolidine-1-carboxylate (10d). Yield (260 mg, 90%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400 MHz): δ 10.42 (s, 1H), 8.14-8.12 (d, 1H), 
7.64-7.56 (m, 2H), 4.24-4.15 (m, 1H), 3.41 (s, 1H), 3.31 (s, 1H), 2.22-
2.17 (m, 1H), 1.93-1.78 (m, 3H), 1.39-1.25 (app s, 9H); 13C NMR 
(DMSO-d6, δ=39.52 ppm, 100 MHz): δ 172.14, 153.63, 153.05, 149.36, 
146.90, 136.55, 135.74, 135.60, 120.93, 118.14, 113.36, 78.65, 60.46, 
46.59, 30.92, 30.11, 27.90, 24.00, 23.40; 19F NMR (DMSO-d6, 376 MHz): 
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δ 39.41, -136.14; HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ 
C16H20F2N2NaO6S: 429.0902; found 429.0900. 
 
tert-Butyl (S)-2-(5-(3-((fluorosulfonyl)oxy)phenyl)-1H-imi-dazol-2-
yl)pyrrolidine-1-carboxylate (10e). Yield (49.8 mg, 80%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400 MHz): δ 8.31-8.25 (d, 2H), 8.14-8.10 (t, 1H), 
7.74-7.70 (t, 1H), 7.63-7.61 (d, 1H), 5.17-5.13 (t, 1H), 3.66-3.61 (m, 1H), 
3.44-3.37 (m, 1H), 2.43-2.34 (m, 1H), 2.11-1.90 (m, 3H), 1.38-1.16 (app 
s, 9H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): δ 153.82, 152.56, 
150.85, 150.11, 131.82, 130.54, 125.80, 121.20, 117.86, 116.57, 79.34, 
53.31, 46.54, 32.94, 27.73, 23.45, 17.96, 16.69, 12.20. 19F NMR (DMSO-
d6, 376 MHz,): 38.53; HRMS (ESI) m/z: Anal. calcd. for [M+H]
+ 
C18H23FN3O5S: 412.1337; found 412.1339. 
 
tert-Butyl (S)-2-(5-(4-fluoro-3-((fluorosulfonyl)oxy)phenyl)-1H-
imidazol-2-yl)pyrrolidine-1-carboxylate (10f). Yield (59.6 mg, 92%); 1H 
NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 12.07-12.00 (d, 1H), 8.03-
8.01 (d, 1H), 7.91-7.87 (m, 1H), 7.66-7.64 (m, 1H), 7.58-7.54 (t, 1H), 
4.82-4.77 (d, 1H), 3.53 (s, 1H), 3.34-3.29 (m, 1H), 2.22 (s, 1H), 1.96-1.85 
(m, 3H), 1.39-1.15 (app s, 9H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 
MHz): δ 153.36, 151.81, 151.06, 149.33, 136.79, 133.63, 125.85, 118.19, 
113.46, 78.26, 55.23, 46.31, 33.29, 31.84, 27.86, 23.83, 23.10; 19F NMR 
(DMSO- d6, 376 MHz): δ 39.85, -134.19; HRMS (ESI) m/z: Anal. calcd. 
for [M+H]+ C18H22F2N3O5S: 430.1243; found 430.1243. 
 
tert-Butyl (S)-2-(5-(4-((fluorosulfonyl)oxy)phenyl)-1H-imidazol-2-
yl)pyrrolidine-1-carboxylate (10g). Yield (100 mg, 80%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 500 MHz): δ 12.50 (s, 1H), 7.93-7.91 (d, 2H), 
7.68-7.64 (d, 1H), 7.57-7.56 (d, 2H), 4.88-4.79 (m, 1H), 3.56-3.53 (t, 1H), 
3.39-3.35 (m, 1H), 2.28-2.17 (m, 1H), 1.99-1.85 (m, 3H), 1.39-1.15 (app 
s, 9H); 13C NMR (DMSO-d6, δ=39.52 ppm, 126 MHz): δ 153.22, 151.07, 
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147.88, 126.11, 121.25, 78.35, 54.90, 46.32, 33.23, 31.81, 28.15, 27.83, 
23.82, 23.12; 19F NMR (DMSO-d6, 376 MHz,): 38.27; HRMS (ESI) m/z: 
Anal. calcd. for [M+H]+ C18H23FN3O5S: 412.1337; found 412.1340. 
 
General procedure for silyl protection. 
A mixture of phenol derivative (2.29 mmol), tert-butyldimethylsilyl 
chloride (3.44 mmol), imidazole (6.87 mmol) in THF (10 mL) was stirred 
at room temperature for 4 h. The mixture was then poured in H2O and 
extracted with CH2Cl2. The organic layer dried over magnesium sulfate, 
and then was purified by the column chromatography (n-hexane / ethyl 
acetate). The residue was obtained as sticky oil. 
 
tert-Butyl (S)-2-((3-((tert-butyldimethylsilyl)oxy)phenyl)carbamoyl)-
pyrrolidine-1-carboxylate (11a). Yield (759 mg, 95%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400 MHz): δ 9.93 (s, 1H), 7.35-7.24 (d, 1H), 
7.16-7.09 (m, 2H), 6.52-6.51 (d, 1H), 4.23-4.13 (m, 1H), 3.44-3.38 (m, 
1H), 3.32-3.30 (m, 1H), 2.21-2.12 (m, 1H), 1.90-1.75 (m, 3H), 1.39-1.26 
(app s, 9H), 0.93 (s, 9H), 0.17 (s, 6H); 13C NMR (DMSO-d6, δ=39.52 ppm, 
100 MHz): δ 171.50, 155.27, 153.11, 140.22, 129.48, 114.63, 112.27, 
110.84, 78.44, 60.40, 46.56, 30.95, 27.89, 25.55, 23.43, 17.95, -4.53; 




bamoyl)pyrrolidine-1-carboxylate (11b). Yield (318 mg, 73%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400 MHz): δ 9.95 (s, 1H), 7.51-7.38 (q, 1H), 7.09 
(s, 2H), 4.22-4.12 (m, 1H), 3.42-3.39 (m, 1H), 3.35-3.30 (m, 1H), 2.21-
2.12 (m, 1H), 1.87-1.75 (m, 3H), 1.39-1.25 (app br s, 9H), 0.95 (s, 9H), 
0.17 (s, 6H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): δ 171.38, 
153.08, 150.51, 148.14, 142.08, 135.72, 115.92, 113.02, 78.41, 60.40, 
46.55, 30.94, 27.85, 25.34, 23.42, 17.95, -4.89; 19F NMR (DMSO-d6, 376 
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MHz): δ -138.76; HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ 
C22H35FN2NaO4Si: 461.2242; found 461.2242. 
 
tert-Butyl (S)-2-((3-((tert-butyldimethylsilyl)oxy)-2-fluorophenyl)car-
bamoyl)pyrrolidine-1-carboxylate (11c). Yield (294 mg, 73%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400 MHz): δ 9.71 (s, 1H), 7.54-7.38 (m, 1H), 
7.02-6.98 (t, 1H), 6.78-6.74 (t, 1H), 4.40-4.33 (m, 1H), 3.43-3.38 (m, 1H), 
2.24-2.08 (m, 1H), 1.91-1.77 (m, 3H), 1.40-1.30 (app br s, 9H), 0.96 (s, 
9H), 0.17 (s, 6H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): δ 
171.82, 153.14, 142.85, 127.23, 123.61, 123.56, 117.48, 116.90, 78.51, 
59.85, 46.54, 31.05, 27.88, 25.38, 23.32, 18.00, -4.84; 19F NMR (DMSO-
d6, 376 MHz): δ -143.28, -144.70; HRMS (ESI) m/z: Anal. calcd. for 
[M+Na]+ C22H35FN2NaO4Si: 461.2242; found 461.2242. 
 
tert-Butyl (S)-2-(5-(4-((tert-butyldimethylsilyl)oxy)phenyl)-1H-
imidazol-2-yl)pyrrolidine-1-carboxylate (11d). Yield (269 mg, 60%); 1H 
NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): δ 11.77 (s, 1H), 7.60-7.59 (d, 
2H), 7.30 (s, 1H), 6.81-6.80 (d, 2H), 4.83-4.75 (m, 1H), 3.56-3.50 (m, 
1H), 3.37-3.34 (m, 1H), 2.23-2.12 (m, 1H), 2.03-1.83 (m, 3H), 1.39-1.16 
(app br s, 9H), 0.95 (s, 9H), 0.18 (s, 6H); 13C NMR (DMSO-d6, δ=39.52 
ppm, 126 MHz): δ 153.70, 153.37, 139.36, 128.82, 125.44, 119.76, 78.12, 
55.20, 46.25, 33.30, 31.76, 27.88, 25.57, 23.79, 23.05, 17.94, -3.21, -4.52; 




1H-imidazol-2-yl)pyrrolidine-1-carboxylate (11e). Yield (638 mg, 69%); 
1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 12.12-11.81 (m, 1H), 7.43 
(s, 1H), 7.35-7.31 (m, 2H), 7.23-7.10 (m, 1H), 4.83-4.76 (m, 1H), 3.53 (s, 
1H), 2.21-2.10 (m, 1H), 1.98-1.84 (m, 3H), 1.39 (s, 4H), 1.15 (s, 9H), 
0.97 (s, 9H), 0.18 (s, 6H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): 
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δ 153.10, 150.70, 142.40, 138.33, 132.30, 118.02, 117.76, 116.26, 116.07, 
111.83, 78.15, 55.30, 46.25, 33.25, 31.81, 27.84, 25.42, 23.73, 23.06, 
18.01, -4.82; 19F NMR (DMSO-d6, 376 MHz): δ -134.91, -136.21; HRMS 
(ESI) m/z: Anal. calcd. for [M+H]+ C24H37FN3O3Si: 462.2583; found 
462.2585. 
tert-Butyl (S)-2-((4-((tert-butyldimethylsilyl)oxy)phenyl)-carbamoyl)-
pyrrolidine-1-carboxylate (11f). Yield (63.0 mg, 92%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 500 MHz): δ 9.83-9.81 (d, 1H), 7.47-7.44 (m, 
2H), 6.79-6.78 (d, 2H), 4.22-4.13 (m, 1H), 3.43-3.40 (m, 1H), 3.32-3.30 
(m, 1H), 2.20-2.13 (m, 1H), 1.91-1.75 (m, 3H), 1.39-1.27 (app s, 9H), 
0.94 (s, 9H), 0.16 (s, 6H); 13C NMR (DMSO-d6, δ=39.52 ppm, 126 MHz): 
δ 170.98, 153.16, 150.73, 132.92, 120.77, 119.73, 78.40, 60.29, 46.55, 
31.02, 27.95, 25.58, 23.96, 23.37, 17.93; HRMS (ESI) m/z: Anal. calcd. 
for [M+Na]+ C22H36N2NaO4Si: 443.2337; found 443.2340. 
 
tert-Butyl (S)-2-(5-(3-((tert-butyldimethylsilyl)oxy)phenyl)-1H-
imidazol-2-yl)pyrrolidine-1-carboxylate (11g). Yield (545 mg, 81%); 1H 
NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): δ 11.88-11.82 (app s, 1H), 7.44-
7.18 (m, 4H), 6.63 (s, 1H), 4.83-4.77 (d, 1H), 3.54 (s, 1H), 3.36 (s, 1H), 
2.22-2.14 (d, 1H), 2.07 (s, 1H), 1.97-1.83 (m, 2H), 1.39-1.16 (app s, 9H), 
0.96 (s, 9H), 0.19 (s, 6H); 13C NMR (DMSO-d6, δ=39.52 ppm, 126 MHz): 
δ 155.26, 153.39, 139.10, 129.35, 117.52, 115.55, 112.01, 78.10, 55.27, 
46.26, 33.27, 31.79, 30.63, 27.84, 25.57, 23.74, 23.08, 17.93; HRMS (ESI) 
m/z: Anal. calcd. for [M+H]+ C24H38N3O3Si: 444.2677; found 444.2681. 
 
General procedure for SuFEx reaction 
A mixture of silylated monomer (0.408 mmol), fosylated monomer 
(0.272 mmol) and DBU (0.05 mmol) in DMF (10 mL) was stirred at 50 ℃ 
for 12 h. The mixture was then poured in 1 N aq HCl solution and 
extracted with CH2Cl2. The organic layer dried over magnesium sulfate, 
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and then was purified by the column chromatography (n-hexane / ethyl 




Yield (76.1 mg, 90%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 
10.28 (s, 1H), 7.72-7.70 (d, 4H), 7.39-7.37 (d, 4H), 4.23-4.16 (m, 2H), 
3.39-3.32 (m, 4H), 2.21-2.16 (t, 2H), 1.86-1.78 (m, 6H), 1.38-1.25 (app 
br s,18H); 13C NMR (DMSO-d6, δ= 39.52 ppm, 100 MHz): δ 172.2, 153.5, 
145.2, 138.8, 121.9, 120.9, 79.0, 63.0, 60.7, 46.8, 31.2, 28.2, 23.7; HRMS 





Yield (1.84 g, 69%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 10.32 
(s, 1H), 8.21-7.77 (m, 3H), 7.59-7.57 (d, 2H), 7.47 (s, 1H), 7.40-7.22 (m, 
1H), 7.12-7.08 (t, 1H), 4.24-4.18 (d, 2H), 3.41 (br s, 4H), 2.20 (s, 2H), 
1.88-1.80 (m, 6H), 1.39-1.24 (app br s, 18H); 13C NMR (DMSO-d6, δ= 
39.52 ppm, 100 MHz): δ 172.0, 153.1, 149.9, 140.8, 130.6, 118.4, 115.3, 
111.4, 78.6, 60.5, 46.6, 30.9, 27.9, 23.4; HRMS (ESI) m/z: Anal. calcd. 




1-carboxylate (12c). Yield (170 mg, 93%); 1H NMR (DMSO-d6, δ=2.5 
ppm, 500 MHz): δ 10.34-10.23 (d, 2H), 7.96-7.88 (m, 1H), 7.75-7.73 (d, 
2H), 7.58-7.55 (t, 1H), 7.49-7.37 (m, 3H), 7.11-7.10 (d, 1H), 4.26-4.16 
(m, 2H), 3.45-3.40 (m, 2H), 3.36-3.31 (m, 2H), 2.23-2.15 (m, 2H), 1.93-
1.77 (m, 6H), 1.39-1.24 (app br s, 18H); 13C NMR (DMSO-d6, δ=39.52 
ppm, 126 MHz): δ 171.80, 153.08, 149.91, 144.95, 144.91, 140.75, 
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138.75, 130.59, 121.56, 120.58, 118.31, 115.45, 111.39, 78.54, 60.41, 
46.58, 30.95, 30.14, 27.90, 23.99, 23.40; HRMS (ESI) m/z: Anal. calcd. 




Yield (217 mg, 78%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 
10.33 (s, 2H), 8.11-8.08 (t, 2H), 7.60-7.58 (d, 2H), 7.53-7.48 (t, 2H), 4.23-
4.13 (m, 2H), 3.42-3.40 (m, 2H), 3.35-3.32 (m, 2H), 2.21-2.18 (m, 2H), 
1.91-1.78 (m, 6H), 1.38-1.23 (app br s, 18H); 13C NMR (DMSO-d6, 
δ=39.52 ppm, 100 MHz): δ 171.92, 153.60, 153.04, 149.87, 147.41, 
136.27, 119.94, 117.90, 113.55, 78.60, 60.45, 46.57, 30.92, 30.11, 27.86, 
23.99, 23.40; 19F NMR (DMSO-d6, 376 MHz): δ -135.44; HRMS (ESI) 





Yield (231 mg, 98%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 
10.12 (s, 2H), 8.00-7.97 (t, 1H), 7.90-7.87 (t, 1H), 7.43-7.40 (t, 2H), 7.35-
7.31 (t, 2H), 4.43-4.34 (m, 2H), 3.44-3.39 (m, 2H), 3.30 (m, 2H), 2.32-
2.11 (m, 2H), 1.91-1.76 (m, 6H), 1.40- 1.29. (br s, 18H); 13C NMR 
(DMSO-d6, δ=39.52 ppm, 100 MHz): δ 172.17, 153.07, 137.06, 128.08, 
124.67, 124.04, 118.49, 78.61, 59.83, 46.55, 31.04, 29.98, 27.90, 23.95, 
23.31; 19F NMR (DMSO-d6, 376 MHz): δ -138.71, -139.67; HRMS (ESI) 





lidine-1-carboxylate (12f). Yield (112 mg, 58%); 1H NMR (DMSO-d6, δ=2.5 
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ppm, 400 MHz): δ 10.33 (s, 1H), 10.11 (s, 1H), 8.12-7.90 (m, 2H), 7.61 (s, 1H), 
7.54-7.49 (t, 1H), 7.40-7.31 (m, 2H), 4.43-4.36 (m, 1H), 4.23-4.13 (m, 1H), 
3.40 (s, 2H), 3.30 (s, 2H), 2.21 (s, 2H), 1.88-1.79 (m, 6H), 1.39-1.23 (app br s, 
18H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): δ 171.95, 153.61, 153.04, 
149.87, 147.41, 137.09, 136.21, 128.05, 124.70, 124.01, 119.90, 117.92, 113.55, 
78.61, 60.45, 46.56, 30.92, 30.12, 27.88, 23.99, 23.39; 19F NMR (DMSO-d6, 
376 MHz): δ -135.48, -138.91, -139.77; HRMS (ESI) m/z: Anal. calcd. for 
[M+Na]+ C32H40F2N4NaO10S: 733.2325; found 733.2325. 
 
Di-tert-butyl 2,2'-(((sulfonylbis(oxy))bis(4,1-phenylene))bis-(1H-imi-
dazole-5,2-diyl))(2S,2'S)-bis(pyrrolidine-1-carboxylate) (12g). Yield 
(32.2 mg, 69%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 11.99 (s, 
2H), 7.88-7.85 (d, 3H), 7.53 (s, 2H), 7.39-7.38 (d, 3H), 7.30-7.27 (d, 1H), 
6.91-6.87 (d, 1H), 4.84-4.77 (d, 2H), 4.03-3.98 (t, 1H), 3.53 (s, 2H), 3.29-
3.25 (m, 1H), 2.22-2.14 (m, 2H), 2.05-1.93 (m, 2H), 1.85-1.71 (m, 4H), 
1.39-1.15 (app br s, 18H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): 
δ 174.6, 153.4, 147.9, 125.7, 121.1, 78.3, 59.6, 55.2, 46.4, 33.3, 31.0, 30.0, 
28.0, 23.9, 23.2; HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ 
C36H45N6O8S: 721.3014; found 721.3014. 
 
Di-tert-butyl 2,2'-(((sulfonylbis(oxy))bis(3,1-phenylene))bis-(1H-imi-
dazole-5,2-diyl))(2S,2'S)-bis(pyrrolidine-1-carboxylate) (12h). Yield 
(54.4 mg, 67%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 12.04-
11.97 (br d, 2H), 8.21-7.76 (t, 4H), 7.64-7.61 (d, 1H), 7.52-7.44 (q, 2H), 
7.37-7.20 (m, 2H), 6.93-6.74 (q, 1H), 4.83-4.77 (d, 2H), 3.53 (s, 2H), 
3.39-3.36 (m, 2H), 2.22-2.15 (m, 2H), 1.98-1.79 (m, 6H), 1.38-1.14 (app 
br s, 18H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): δ 153.4, 150.4, 
138.1, 131.3, 130.5, 123.5, 119.2, 117.8, 116.4, 116.2, 78.2, 55.2, 46.3, 
33.3, 27.9, 23.1; HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ 






yl)pyrrolidine-1-carboxylate (12i). Yield (721 mg, 52%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400 MHz): δ 8.25-8.04 (m, 6H), 7.66-7.51 (d, 
4H), 5.12 (s, 2H), 3.63 (s, 2H), 3.41 (s, 2H), 2.38 (s, 2H), 2.07-1.91 (m, 
6H), 1.38-1.15. (app br s, 18H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 
MHz): δ 153.71, 152.45, 150.67, 150.56, 150.22, 149.56, 131.39, 127.37, 
124.78, 122.07, 117.89, 116.19, 115.71, 79.19, 52.97, 46.45, 32.89, 31.98, 
27.70, 23.92, 23.38; HRMS (ESI) m/z: Anal. calcd. for [M+H]+ 




Yield (305 mg, 63%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 
12.01 (s, 2H), 7.92-7.91 (d, 2H), 7.82 (s, 2H), 7.58 (s, 2H), 7.52-7.47 (t, 
2H), 4.82-4.76 (d, 2H), 3.52 (s, 2H), 3.37-3.17 (m, 2H), 2.22-2.13 (m, 
2H), 1.95-1.84 (t, 2H), 1.37-1.14(app br s, 18H); 13C NMR (DMSO-d6, 
δ=39.52 ppm, 100 MHz): δ 153.35, 152.22, 150.24, 136.98, 136.87, 
133.21, 125.00, 118.39, 117.68, 113.11, 78.24, 55.22, 46.29, 33.23, 31.78, 
27.83, 23.77, 23.07; 19F NMR (DMSO-d6, 376 MHz): δ -133.22; HRMS 




nediyl))bis(carbonyl))(2S,2'S)-bis(pyrrolidine-1-carboxylate) (12k). Yield 
321 mg (75%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 9.66-9.61 (d, 2H), 
7.41 (s, 2H), 7.37-7.33 (t, 2H), 7.26-7.24 (d, 2H), 4.31-4.29 (t, 2H), 3.42 (s, 2H), 
3.34 (s, 2H), 2.25-2.23 (br d, 2H), 2.11 (s, 6H), 1.97-1.82 (m, 6H), 1.41-1.35 
(app br s, 18H). 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): 171.7, 153.8, 
153.2, 148.6, 138.3, 126.8, 125.9, 125.1, 118.1, 78.6, 59.9, 46.6, 31.3, 30.0, 
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28.1, 24.1, 23.2, 11.4. HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ 
C34H46N4NaO10S: 725.2827; found 725.2826. 
 
Di-tert-butyl 2,2'-((((sulfonylbis(oxy))bis(4-methyl-3,1-phenyl-ene))bis-
(azanediyl))bis(carbonyl))(2S,2'S)-bis(pyrrolidine-1-carboxylate) (12l). Yield 
229 mg (72%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 10.22 (s, 2H), 7.95 
(s, 2H), 7.54-7.48 (q, 2H), 7.34-7.32 (d, 2H), 4.24-4.13 (m, 2H), 3.42-3.31 (m, 
4H), 2.20-2.17 (d, 8H), 1.91-1.77 (m, 6H), 1.38-1.23 (app br s, 18H). 13C NMR 
(DMSO-d6, δ=39.52 ppm, 100 MHz): 171.8, 153.1, 148.2, 138.4, 131.9, 124.5, 
118.5, 111.6, 78.5 60.4, 46.5, 30.9, 27.9, 23.4, 15.1. HRMS (ESI) m/z: Anal. 
calcd. for [M+Na]+ C34H46N4NaO10S: 725.2827; found 725.2827. 
 
General procedure for synthesis of inhibitors 
A mixture of precursor (0.151 mmol) in CF3CO2H (3 mL) / CH2Cl2 (3 mL) 
was stirred at room temperature for 30 m. The volatile component was removed 
in vacuo, 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.392 mmol), 
Hydroxy-benzotriazole hydrate (0.392 mmol), Capping group (0.362 mmol) 
were added in batches over 4 min to a solution of N,N-Diisopropylethylamine 
(0.754 mmol) in CH2Cl2 (10 mL) and the reaction mixture stirred at room 
temperature for overnight. The mixture was then poured in 1 N aq HCl solution 
and extracted with CH2Cl2. The organic layer dried over magnesium sulfate, 
and then was purified by the column chromatography (CH2Cl2/ MeOH). The 
residue was obtained as solid. 
 
Bis(4-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidine-2-carbox-amido)phenyl) 
sulfate (16, BMK-21057). Yield 85.5 mg (69%); 1H NMR (DMSO-d6, δ=2.5 
ppm, 400 MHz): 10.30 (s, 2H), 7.72-7.71 (d, 4H), 7.39-7.32 (m, 6H), 4.44 (s, 
2H), 4.05-4.02 (t, 2H), 3.81 (s, 2H), 3.63 (s, 2H), 3.52 (s, 6H), 2.19-2.08 (m, 
2H), 1.99-1.89 (m, 8H), 1.26-1.23 (m, 2H), 0.94-0.88 (m, 12H). 13C NMR 
(DMSO-d6, δ=39.52 ppm, 125 MHz): 170.7, 170.3, 156.8, 144.8, 138.7, 121.5, 
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120.3, 60.2, 57.9, 51.4, 47.2, 29.9, 29.4, 24.6, 18.9, 18.6. HRMS (ESI) m/z: 
Anal. calcd. for [M+H]+ C36H49N6O12S: 789.3124; found 789.3129. 
 
Bis(4-((S)-1-((methoxycarbonyl)-D-valyl)pyrrolidine-2-carbox-amido)phenyl) 
sulfate (17, BMK-21013). Yield (58.0 mg, 86 %); 1H NMR (DMSO-d6, δ=2.5 
ppm, 400 MHz): 10.00 (s, 2H), 7.74-7.72 (d, 4H), 7.42-7.34 (q, 6H), 4.42-4.40 
(d, 2H), 4.11-4.07 (t, 2H), 3.79 (s, 2H), 3.63-3.60 (d, 2H), 3.54 (s, 6H), 2.13-
1.91 (m, 10H), 0.89-0.86 (t, 10H), 0.80-0.78 (d, 1H), 0.72-0.70 (d, 1H). 13C 
NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): 170.69, 170.2, 156.9, 145.0, 138.6, 
121.5, 120.5, 60.3, 58.0, 54.9, 51.6, 47.1, 29.7, 29.4, 24.3, 19.1, 18.3. HRMS 




2-carboxamido)phenyl) sulfate (18, BMK-21007). Yield 37.6 mg (59%); 1H 
NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 10.14 (s, 1H), 7.76-7.52 (m, 7H), 
7.42-7.32 (m, 12H), 7.23-7.09 (m, 1H), 5.51-5.49 (d, 2H), 4.40-4.38 (d, 2H), 
3.82 (br s, 2H), 3.54 (s, 6H), 3.20-3.18 (d, 2H), 2.04-1.80 (m, 8H). 13C NMR 
(DMSO-d6, δ=39.52 ppm, 100 MHz): 170.6, 168.2, 156.4, 144.9, 138.7, 136.9, 
128.6, 128.5, 128.1, 121.6, 120.5, 62.8, 62.8, 60.8, 56.7, 51.6, 46.9, 29.3, 29.1, 
24.7. HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ C42H44N6NaO12S: 879.2630; 
found 879.2630.  
 
Bis(4-(2-((S)-1-((R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-pyrro-
lidin-2-yl)-1H-imidazol-5-yl)phenyl) sulfate (19, BMK-21016). Yield (56.1 
mg, 43%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 8.14 (s, 1H), 8.07 (s, 
1H), 7.98-7.96 (d, 2H), 7.92-7.85 (q, 2H), 7.80-7.78 (d, 1H), 7.71-7.60 (m, 5H), 
7.39 (s, 4H), 7.35-7.34 (d, 1H), 7.30-7.29 (d, 4H), 7.04 (s, 1H), 5.54-5.50 (t, 
2H), 5.21-5.19 (m, 2H), 3.96-3.77 (m, 2H), 3.51 (s, 6H), 3.39-3.14 (m, 2H), 
2.38-2.23 (m, 2H), 2.09-1.86 (m, 6H). 13C NMR (DMSO-d6, δ=39.52 ppm, 100 
MHz): 169.0, 158.6, 156.3, 149.2, 149.4, 136.8, 131.43, 128.68, 128.32, 128.12, 
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127.45, 127.25, 122.10, 115.93, 57.00, 53.48, 51.62, 47.00, 30.81, 24.14. 




yl)phenyl) sulfate (20, BMK-21015). Yield 76.9 mg (74%); 1H NMR (DMSO-
d6, δ=2.5 ppm, 400 MHz): 8.09 (s, 2H), 7.96-7.94 (d, 4H), 7.65-7.62 (d, 3H), 
7.58-7.52 (m, 1H), 7.25-7.23 (d, 2H), 5.19-5.16 (q, 2H), 4.19-4.15 (t, 2H), 3.91-
3.83 (m, 2H), 3.70-3.61 (m, 2H), 3.53 (s, 6H), 2.38-2.36 (t, 2H), 2.08-1.94 (m, 
8H), 0.90-0.85 (q, 10H), 0.71-0.70 (d, 1H), 0.35-0.34 (d, 1H).13C NMR 
(DMSO-d6, δ=39.52 ppm, 100 MHz): 170.8, 156.8, 149.6, 149.6, 127.3, 122.0, 
115.8, 57.8, 53.2, 51.6, 47.0, 30.9, 29.7, 24.4, 19.3, 17.8. HRMS (ESI) m/z: 
Anal. calcd. for [M+H]+ C40H51N8O10S: 835.3443; found 835.3444. 
 
Bis(4-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-
yl)phenyl) sulfate (21, BMK-21030). Yield 25 mg, (13%); 1H NMR (DMSO-
d6, δ=2.5 ppm, 400 MHz): 11.88 (s, 2H), 7.88-7.81 (m, 4H), 7.52 (s, 2H), 7.39-
7.37 (d, 4H), 7.29-7.27 (d, 2H), 5.07 (s, 2H), 4.08-3.99 (m, 2H), 3.80-3.74 (m, 
4H), 3.54 (s, 6H), 2.14 (s, 2H), 1.99-1.91 (m, 6H), 1.86-1.76 (m, 2H), 0.89-0.83 
(q, 12H). 13C NMR (DMSO-d6, δ=39.52 ppm, 100 MHz): 173.5, 170.4, 170.2, 
156.8, 147.9, 125.7, 121.2, 59.2, 58.0, 54.2, 51.5, 46.8, 30.9, 29.9, 24.3, 19.0, 




2-carboxamido)phenyl) sulfate (22, BMK-21014). Yield 1.08 g (70%); 1H 
NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 10.25 (s, 1H), 7.88-7.85 (d, 3H), 
7.72-7.70 (d, 2H), 7.63-7.61 (d, 2H), 7.50-7.47 (t, 2H), 7.40-7.30 (m, 8H), 7.16-
7.10 (q, 2H), 5.50-5.48 (d, 2H), 4.38-4.36 (m, 2H), 3.81-3.73 (d, 2H), 3.52 (s, 
6H), 3.20-3.17 (m, 2H), 2.02-1.79 (m, 8H). 13C NMR (DMSO-d6, δ=39.52 ppm, 
100 MHz): 170.8, 168.4, 149.9, 140.7, 137.2, 130.7, 128.6, 128.4, 128.0, 118.4, 
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115.5, 111.3, 60.7, 56.7, 51.6, 47.0, 29.2, 24.3. HRMS (ESI) m/z: Anal. calcd. 
for [M+Na]+ C42H44N6NaO12S: 879.2630; found 879.2629. 
 
Bis(3-((S)-1-((S)-2-((methoxycarbonyl)amino)-3,3-dimethyl-butanoyl)-
pyrrolidine-2-carboxamido)phenyl) sulfate (23, BMK-21042). Yield 29.7 mg 
(22%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 10.41-10.16 (d, 2H), 7.88-
7.82 (d, 2H), 7.62-7.60 (d, 2H), 7.48-7.44 (t, 2H), 7.27-7.10 (q, 4H), 4.45-4.41 
(t, 2H), 4.23-4.20 (d, 2H), 3.79-3.76 (m, 2H), 3.65-3.62 (m, 2H), 3.54 (s, 6H), 
2.20-2.14 (m, 2H), 2.02-1.84 (m, 6H), 0.96 (s, 18H). 13C NMR (DMSO-d6, 
δ=39.52 ppm, 125 MHz): 170.9, 169.6, 156.9, 149.9, 140.9, 130.7, 118.2, 115.2, 
111.1, 60.3, 59.1, 51.5, 47.9, 34.7, 29.5, 26.4, 26.2, 24.8. HRMS (ESI) m/z: 
Anal. calcd. for [M+Na]+ C38H52N6NaO12S: 839.3256; found 839.3255. 
 
Bis(3-(2-((S)-1-((R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-
pyrrolidin-2-yl)-1H-imidazol-5-yl)phenyl) sulfate (24, BMK-21019). Yield 
97.2 mg (67%). 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 12.05 (br s, 1H), 
7.96 (s, 1H), 7.94-7.64 (m, 5H), 7.50 (s, 1H), 7.39-7.25 (m, 13H), 7.00-6.93 (d, 
1H), 5.49-5.40 (m, 2H), 5.14-5.05 (d, 2H), 4.18-3.67 (m, 2H), 3.55 (s, 6H), 
3.43-3.41 (t, 1H), 3.11 (s, 1H), 1.98-1.72 (m, 8H). 13C NMR (DMSO-d6, 
δ=39.52 ppm, 100 MHz): 173.4, 172.1, 168.4, 156.0, 150.5, 149.6, 137.2, 130.6, 
128.4, 127.7, 124.2, 123.6, 119.0, 116.3, 109.8, 72.3, 60.3, 58.1, 57.0, 55.2, 
51.6, 46.7, 31.1, 29.2, 24.0. HRMS (ESI) m/z: Anal. calcd. for [M+H]+ 
C46H47N8O10S: 903.3130; found 903.3133. 
 
Bis(3-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3,3-dimethyl-butanoyl)-
pyrrolidin-2-yl)-1H-imidazol-5-yl)phenyl) sulfate (25, BMK-21032). Yield 
43.8 mg (73%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 8.07-7.83 (m, 1H), 
7.78-7.71 (m, 4H), 7.66-7.63 (t, 1H), 7.57-7.40 (m, 3H), 7.29-7.21 (m, 2H), 
7.08-7.06 (d, 1H), 5.42-5.05 (m, 2H), 4.21-4.19 (d, 2H), 3.81-3.68 (m, 4H), 
3.54 (s, 6H), 2.18-2.08 (m, 3H), 2.02-1.66 (m, 5H), 0.94-0.88 (app br s, 18H). 
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13C NMR (DMSO-d6, δ=39.52 ppm, 125 MHz): 172.7, 169.7, 156.9, 150.4, 
130.5, 128.6, 127.4, 125.1, 124.5, 123.5, 119.6, 119.1, 116.4, 109.9, 83.4, 62.8, 
59.2, 53.8, 52.5, 51.5, 47.5, 34.6, 30.9, 26.3, 24.4, 16.5. HRMS (ESI) m/z: Anal. 
calcd. for [M+H]+ C42H55N8O10S: 863.3756; found 863.3757. 
 
Bis(3-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-
yl)phenyl) sulfate (26, BMK-21025). Yield 60.8 mg (44%); 1H NMR (DMSO-
d6, δ=2.5 ppm, 400 MHz): 11.98 (br s, 1H), 7.98-7.96 (d, 1H), 7.77-7.75 (d, 
3H), 7.71-7.69 (d, 1H), 7.59 (s, 1H), 7.53-7.45 (q, 3H), 7.42-7.38 (t, 1H), 7.28-
7.26 (d, 1H), 7.21-7.18 (d, 1H), 5.06 (s, 2H), 4.05-4.01 (t, 2H), 3.86-3.76 (m, 
4H), 3.53 (s, 6H), 2.12-2.07 (m, 4H), 1.94-1.87 (m, 6H), 0.91-0.84 (m, 8H), 
0.81-0.80 (d, 4H). 13C NMR (DMSO-d6, δ=39.52 ppm, 125 MHz): 170.4, 156.8, 
150.4, 149.8, 131.1, 129.9, 127.8, 126.6, 123.9, 118.8, 116.8, 110.3, 57.7, 57.2, 
54.7, 53.6, 51.3, 29.9. HRMS (ESI) m/z: Anal. calcd. for [M+H]+ C40H51N8O10S: 
835.3443; found 835.3442. 
 
Bis(3-((S)-1-((R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-pyrrolidine-
2-carboxamido)-2-methylphenyl) sulfate (27, BMK-21028). Yield 84.5 mg 
(85%); 1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): 9.73-9.56 (d, 2H), 7.76-
7.58 (m, 2H), 7.48-7.21 (m, 15H), 7.12-6.67 (m, 1H), 5.52-5.43 (m, 2H), 4.65-
4.47 (m, 2H), 3.85 (s, 1H), 3.75-3.62 (m, 1H), 3.55-3.50 (app br s, 6H), 3.17 (s, 
2H), 2.16 (s, 6H), 2.00-1.73 (m, 8H). 13C NMR (DMSO-d6, δ=39.52 ppm, 125 
MHz): 170.4, 168.8, 156.1, 148.6, 138.2, 137.1, 128.6, 128.1, 126.8, 126.0, 
125.3, 118.3, 60.6, 56.8, 51.6, 47.0, 29.1, 24.3, 11.3. HRMS (ESI) m/z: Anal. 
calcd. for [M+Na]+ C44H48N6NaO12S: 907.2943; found 907.2940. 
 
Bis(5-((S)-1-((R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-pyrrolidine-
2-carboxamido)-2-methylphenyl) sulfate (28, BMK-21020). Yield 105 mg 
(74%). 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 10.36-10.19 (d, 2H), 7.94-
7.89 (d, 2H), 7.75-7.67 (q, 2H), 7.58 (s, 2H), 7.42-7.41 (d, 3H), 7.36-7.07 (m, 
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9H), 5.52-5.47 (t, 2H), 4.47-4.38 (d, 2H), 3.82-3.66 (d, 2H), 3.53 (s, 6H), 3.18-
3.09 (d, 2H), 2.22 (s, 6H), 1.99-1.78 (m, 8H). 13C NMR (DMSO-d6, δ=39.52 
ppm, 100 MHz): 170.6, 168.4, 156.1, 148.3, 138.5, 136.9, 132.0, 128.6, 128.1, 
124.6, 118.5, 111.4, 60.7, 56.7, 51.6, 47.0, 29.3, 24.3, 15.3. HRMS (ESI) m/z: 




amino)-2-phenylacetyl)pyrrolidine-2-carboxamido)-phenyl) sulfate (29, 
BMK-21022). Yield (106.7 mg, 83 %); 1H NMR (DMSO-d6, δ=2.5 ppm, 
400 MHz): δ 10.63-10.31/10.27/10.17 (m/s/s, 0.87H+0.5H+0.57H), 7.91-
7.89 (d, 1H), 7.80-7.72 (m, 3H), 7.68-7.56 (m, 2H), 7.50-7.26 (m, 12H), 
7.17-7.05 (m, 2H), 5.53-5.42/5.37-5.34/4.94-4.90 (m/t/t, 
1.61H+0.19H+0.18H), 4.61-4.39 (m, 2H), 3.86-3.81 (qui, 1H), 3.73-3.66 
(m, 1H), 3.54 (s, 6H), 3.22-3.17 (q, 1H), 3.13-3.09 (t, 1H), 2.32-2.14 (m, 
1H), 2.07-1.76 (m, 8H), 1.23/0.85 (2 s, 0.30H+0.10H); 13C NMR 
(DMSO-d6, δ=39.52 ppm, 100 MHz): δ 170.59, 168.40, 156.09, 149.89, 
145.03, 140.74, 138.70, 137.21, 130.65, 128.62, 128.06, 121.61, 120.65, 
118.31, 115.50, 111.35, 60.71, 56.71, 51.65, 46.98, 29.25, 24.30; HRMS 





amido)phenyl) sulfate (30, BMK-21023). Yield (46.7 mg, 71 %); 1H 
NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 10.64/10.54/10.13/10.02 (4 s, 
0.2H+0.2H+0.86H+0.82H), 7.87 (s, 1H), 7.76-7.73 (d, 2H), 7.61-7.59 (d, 
2H), 7.51-7.36 (m, 5H), 7.14-7.08 (m, 1H), 4.43-4.39 (q, 2H), 4.12-4.07 
(t, 2H), 3.79(s, 2H), 3.64-3.58 (q, 2H), 3.55-3.53 (app s, 6H), 3.48-3.45 
(m, 1H), 2.16-2.08 (m, 2H), 2.04-1.92 (m, 8H), 0.89-0.86 (t, 10H), 0.80-
0.77 (t, 1H), 0.72-0.68 (m, 1H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 
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MHz): δ 171.01, 170.71, 170.24, 156.92, 149.85, 144.94, 140.71, 138.67, 
130.61, 121.57, 120.50, 118.19, 115.42, 111.22, 60.32, 60.27, 58.01, 
51.56, 47.11, 29.76, 29.41, 29.37, 24.39, 24.35, 19.09, 18.32; HRMS (ESI) 




acetyl)pyrrolidine-2-carboxamido)phenyl) sulfate (31, BMK-21036). 
Yield (41.0 mg, 49%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 
10.21 (s, 1H), 10.10 (s, 1H), 8.02-7.97 (q, 2H), 7.72-7.66 (q, 2H), 7.41-
7.40 (m, 6H), 7.37-7.29 (m, 7H), 7.27-7.25/7.12-7.10 (2 d, 0.48H+0.35H), 
5.51-5.45 (q, 2H), 4.69-4.67 (m, 1H), 4.57-4.55 (m, 1H), 3.81 (s, 1H), 
3.71-3.65 (m, 1H), 3.53 (s, 6H), 3.20-3.14 (q, 1H), 3.10-3.08 (d, 1H), 
2.18-2.16 (d, 1H), 2.03-1.78 (m, 7H), 1.23/0.85 (2 s, 2.02H+0.62H); 13C 
NMR (DMSO-d6, δ=39.52 ppm, 126 MHz): δ 170.92, 168.45, 168.25, 
156.33, 155.97, 136.74, 128.60, 128.38, 128.35, 127.99, 124.76, 123.15, 
118.26, 118.03, 60.26, 56.65, 51.55, 46.85, 29.14, 24.69, 24.27; 19F NMR 
(DMSO-d6, 376 MHz): δ -74.67, -139.84, -139.84; HRMS (ESI) m/z: 
Anal. calcd. for [M+Na]+ C42H42F2N6NaO12S: 915.2442; found 915.2445. 
 
Bis(2-fluoro-5-((S)-1-((R)-2-((methoxycarbonyl)amino)-2-phenyl-
acetyl)pyrrolidine-2-carboxamido)phenyl) sulfate (32, BMK-21024). Yield 
(63.4 mg, 52 %); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 
10.64/10.47/10.32/10.28 (4 s, 0.06H+0.3H+0.33H+1.19H), 8.13-8.01 (m, 2H), 
7.87-7.72 (m, 2H), 7.65 (s, 2H), 7.55-7.50 (t, 2H), 7.42-7.29 (m, 8H), 7.25-
7.23/7.06-7.03 (2 m, 0.52H+0.74H) 7.06-7.04 (t, 1H), 5.52-5.47/5.35-5.33/4.87-4.85 
(m/d/d, 1.56H+0.26H+0.20H), 4.48-4.35 (m, 2H), 3.84-3.81 (m, 2H), 3.53 (s, 6H), 
3.20-3.09 (m, 2H), 2.04-1.77 (m, 8H), 1.23/0.85 (2 s, 0.35H+0.07H); 13C NMR 
(DMSO-d6, δ=39.52 ppm, 100 MHz): δ 170.71, 168.39, 156.07, 149.70, 147.73, 137.20, 
136.26, 128.59, 128.03, 119.96, 117.92, 113.47, 60.69, 56.67, 51.63, 46.96, 29.21, 
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24.31; 19F NMR (DMSO-d6, 376 MHz): δ -135.20; HRMS (ESI) m/z: Anal. calcd. for 





phenyl) sulfate (33, BMK-21047). Yield (112 mg, 58%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400 MHz): δ 10.46/10.27/10.21/10.11 (4 s, 
0.57H+0.53H+0.32H+0.36H), 8.11-7.80 (m, 2H), 7.74-7.64 (m, 3H), 
7.55-7.50 (t, 1H), 7.39-7.21 (m, 11H), 7.09-7.04 (d, 2H), 5.51-5.20/5.10-
5.08/4.86-4.84 (m/d/d, 1.96H+0.06H+0.08H), 4.68/4.57-4.55/4.46-
4.43/4.36-4.34 (4 m, 0.28H+0.40H+0.46H+0.62H), 3.81-3.67 (m, 2H), 
3.52 (s, 6H), 3.17-3.08 (m, 2H), 2.27-2.16 (m, 1H), 1.99-1.80 (m, 7H), 
1.23/0.85 (2 s, 0.31H+0.10H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 
MHz): δ 170.92, 168.38, 156.30, 156.05, 149.85, 147.40, 137.16, 136.77, 
136.25, 136.08, 128.58, 128.35, 128.01, 124.81, 123.48, 123.06, 119.72, 
117.96, 117.78, 113.31, 60.67, 56.65, 51.54, 46.94, 29.18, 24.30; 19F 
NMR (DMSO-d6, 376 MHz): δ -73.82, -135.52, -139.50, -139.97; HRMS 




carboxamido)phenyl) sulfate (34, BMK-21027). Yield (77.7 mg, 80 %); 
1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): δ 10.63/10.15 (2 s, 
0.35H+1.62H), 8.04 (s, 2H), 7.63-7.61 (d, 2H), 7.52-7.48 (t, 2H), 7.36-
7.35 (d, 2H), 4.38-4.36 (d, 2H), 4.11-4.07 (t, 2H), 3.78-3.74 (m, 2H), 
3.63-3.57 (m, 2H), 3.53 (s, 6H), 2.15-2.08 (m, 2H), 2.08-1.84 (m, 8H), 
0.88-0.86 (t, 10H), 0.77-0.76 (d, 1H), 0.67-0.67 (d, 1H); 13C NMR 
(DMSO-d6, δ=39.52 ppm, 126 MHz): δ 170.87, 170.22, 156.93, 149.64, 
147.66, 136.25, 120.42, 119.35, 117.33, 113.56, 113.09, 60.63, 59.92, 
57.96, 51.42, 29.95, 24.44, 19.09, 18.29; 19F NMR (DMSO-d6, 376 MHz): 
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δ -135.35; HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ 




valyl)pyrrolidine-2-carboxamido)phenyl) sulfate (35, BMK-21048). 
Yield (40.3 mg, 39%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 
10.64/10.45/10.16/9.97 (4 s, 0.16H+0.22H+0.81H+0.71H), 8.08-8.07 (d, 
1H), 7.99-7.82 (m, 1H), 7.64-7.60 (m, 1H), 7.53-7.48 (t, 1H), 7.44-7.28 
(m, 4H), 5.17-5.15/5.03-5.01/4.60-4.58 (3 d, 0.14H+0.16H+0.77H), 
4.38-4.37 (d, 1H), 4.12-4.07 (t, 2H), 3.87-3.71 (m, 2H), 3.64-3.58 (m, 1H), 
3.53-3.50 (app s, 6H), 3.46-3.45(m, 1H) 2.21-2.09 (m, 2H), 1.99-1.81 (m, 
8H), 1.23 (s, 0.32H), 0.89-0.66 (m, 12H); 13C NMR (DMSO-d6, δ=39.52 
ppm, 100 MHz): δ 170.90, 170.22, 156.84, 149.90, 147.44, 146.40, 
143.89, 137.12, 136.06, 128.18, 124.71, 123.31, 119.81, 117.89, 113.39, 
60.28, 58.00, 51.54, 47.09, 29.75, 24.38, 19.07, 18.30; 19F NMR (DMSO-
d6, 376 MHz): δ -134.98, -135.41, -138.11, -139.92; HRMS (ESI) m/z: 
Anal. calcd. for [M+Na]+ C36H46F2N6NaO12S: 847.2755; found 847.2754. 
 
Bis(2-fluoro-3-((S)-1-((methoxycarbonyl)-D-valyl)pyrro-lidine-2-
carboxamido)phenyl) sulfate (36, BMK-21038). Yield (97.9 mg, 74%); 
1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 10.45/10.14/9.97 (3 s, 
0.33H+0.20H+1.44H), 7.98-7.81 (m, 2H), 7.48-7.29 (m, 6H), 5.17-
5.15/4.60-4.58 (2 d, 0.27H+1.48H), 4.12-4.07 (t, 1H), 3.87-3.79 (m, 2H), 
3.66-3.60 (m, 4H), 3.50 (s, 6H), 2.25-2.11 (m, 2H), 1.98-1.85 (m, 8H), 
1.23 (s, 0.15H), 0.89-0.71 (m, 12H); 13C NMR (DMSO-d6, δ=39.52 ppm, 
100 MHz): δ 170.53, 156.87, 146.52, 144.01, 137.14, 128.15, 124.70, 
123.42, 118.19, 59.91, 58.04, 51.45, 48.64, 47.13, 29.75, 29.16, 24.37, 
19.08, 18.32; 19F NMR (DMSO-d6, 376 MHz): δ -78.40, -142.54, -144.44; 
HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ C36H46F2N6NaO12S: 





1H-imidazol-5-yl)phenyl) sulfate (37, BMK-21046). Yield (34.5 mg, 
52%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 8.08-8.06 (d, 2H), 
8.01 (s, 2H), 7.92-7.91 (d, 2H), 7.80 (s, 1H), 7.73-7.68 (t, 1H), 7.59-7.46 
(m, 1H), 7.25-7.23 (d, 1H), 5.69-5.67/5.14-5.12 (2 d, 0.35H+1.32H), 
4.17-4.13 (t, 2H), 3.87-3.86 (d, 2H), 3.68-3.62 (q, 2H), 3.53 (s, 6H), 2.32 
(s, 2H), 2.08-1.67 (m, 8H), 1.23 (s, 0.47H), 0.90-0.29 (m, 12H); 13C NMR 
(DMSO-d6, δ=39.52 ppm, 100 MHz): δ 170.71, 156.88, 149.66, 137.07, 
136.94, 126.54, 120.06, 118.57, 115.78, 57.87, 53.48, 51.58, 46.95, 30.88, 
29.69, 24.28, 19.25, 18.57, 18.41, 17.93; 19F NMR (DMSO-d6, 376 MHz): 
δ -74.27; HRMS (ESI) m/z: Anal. calcd. for [M+H]+ C40H49F2N8O10S: 
871.3255; found 871.3256. 
 
Bis(2-fluoro-5-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrro-lidin-2-yl)-
1H-imidazol-5-yl)phenyl) sulfate (38, BMK-21044). Yield (90.1 mg, 
48%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 8.06-8.05 (d, 2H), 
7.99 (s, 2H), 7.90-7.88 (d, 2H), 7.71-7.67 (t, 2H), 7.30-7.28 (d, 2H), 
5.45/5.11-5.08 (m/t, 0.13H+1.99H), 4.10-4.06 (t, 2H), 3.86-3.76 (m, 4H), 
3.53 (s, 6H), 2.32-2.28 (t, 2H), 2.14-2.10 (m, 2H), 2.07-1.94 (m, 6H), 1.23 
(s, 0.46H), 0.81-0.75 (q, 12H); 13C NMR (DMSO-d6, δ=39.52 ppm, 100 
MHz): δ 170.95, 158.36, 158.03, 156.88, 149.87, 137.07, 136.93, 126.37, 
119.84, 118.72, 118.55, 57.93, 53.34, 51.52, 47.05, 31.00, 29.30, 24.58, 
19.13, 17.99; 19F NMR (DMSO-d6, 376 MHz): δ -78.32, -138.05; HRMS 




phenylacetyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)phenyl) sulfate (39, 
BMK-21045). Yield (34.5 mg, 73%); 1H NMR (DMSO-d6, δ=2.5 ppm, 
400 MHz): δ 8.11-8.03 (m, 4H), 7.98-7.93 (m, 2H), 7.79-7.71 (m, 2H), 
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7.68-7.64 (t, 2H), 7.39-7.34 (m, 6H), 7.29 (s, 2H), 6.99 (s, 2H), 5.65-
5.63/5.50-5.49/5.40-5.38 (3 d, 0.51H+1.37H+0.49H), 5.17-5.16 (d, 2H), 
3.93-3.82 (m, 2H), 3.53-3.51 (app s, 6H), 3.18-3.12 (q, 2H), 2.22-2.15 (m, 
2H), 2.02-2.00 (d, 4H), 1.87 (s, 2H), 1.23 (s, 0.72H); 13C NMR (DMSO-
d6, δ=39.52 ppm, 100 MHz): δ 168.88, 155.95, 151.56, 149.53, 137.11, 
136.95, 128.67, 128.27, 128.11, 127.78, 126.70, 120.27, 118.82, 118.63, 
115.87, 56.99, 53.80, 51.61, 46.94, 30.91, 24.10; 19F NMR (DMSO-d6, 
376 MHz): δ -78.97, -133.12; HRMS (ESI) m/z: Anal. calcd. for [M+H]+ 





imidazol-5-yl)phenyl) sulfate (40, BMK-21040). Yield (53.3 mg, 35%); 
1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 8.19-8.06 (m, 2H), 7.98-
7.96 (d, 2H), 7.91-7.83 (m, 2H), 7.73-7.64 (m, 5H), 7.39-7.25 (m, 10H), 
7.03 (s, 1H), 5.53-5.49/5.45-5.43/5.40-5.38 (t/d/d, 1.51H+0.25H+0.18H), 
5.18 (m, 2H), 3.91-3.85 (d, 1H), 3.80-3.71 (m, 1H), 3.54-3.51 (app br s, 
6H), 3.46-3.38 (d, 1H), 3.17-3.15 (d, 1H), 2.37-2.22 (m, 2H), 2.08-1.89 
(m, 6H), 1.23 (s, 0.20H); 13C NMR (DMSO-d6, δ=39.52 ppm, 126 MHz): 
δ 168.99, 156.34, 155.97, 150.33, 149.40, 136.86, 131.50, 128.69, 128.62, 
128.31, 128.12, 127.79, 127.44, 127.23, 124.83, 122.11, 122.06, 117.94, 
115.90, 57.00, 56.73, 53.48, 51.62, 47.01, 30.88, 24.14; HRMS (ESI) m/z: 




1H-imidazol-5-yl)phenyl) sulfate (41, BMK-21043). Yield (107 mg, 
86%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 8.13-8.08 (d, 2H), 
7.95-7.87 (m, 4H), 7.78-7.63 (m, 3H), 7.54-7.48 (m, 1H), 7.30-7.23 (m, 
2H), 5.80-5.74/5.19-5.10 (d/m, 0.25H+1.73H), 4.18-4.07 (m, 2H), 3.88-
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3.78 (m, 2H), 3.68-3.66 (d, 2H), 3.53 (s, 6H), 2.36 (s, 2H), 2.08-1.96 (m, 
8H), 1.23 (s, 0.39H), 0.90-0.68 (m, 12H), 0.33 (s, 1H); 13C NMR (DMSO-
d6, δ=39.52 ppm, 100 MHz): δ 170.80, 158.49, 158.15, 156.87, 150.32, 
149.57, 131.43, 127.33, 124.70, 122.08, 120.79, 117.78, 116.21, 115.85, 
57.84, 53.19, 51.59, 47.00, 30.89, 29.70, 24.34, 19.28, 17.89; HRMS (ESI) 




1H-imidazol-5-yl)phenyl) sulfate (42, BMK-21039). Yield (110 mg, 
54%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 12.37-12.39/12.16-
12.13/11.92-11.86 (3 d, 0.14H+0.18H+1.51H), 7.85-7.83 (d, 2H), 7.76-
7.73 (m, 2H), 7.61 (s, 1H), 7.54 (s, 1H), 7.48-7.44 (t, 1H), 7.39-7.36 (d, 
2H), 7.31-7.26 (t, 2H), 7.19-7.16 (q, 1H), 5.22/5.08-5.03 (2 m, 
0.14H+1.86H), 4.11-4.00 (m, 2H), 3.78 (s, 2H), 3.53 (s, 6H), 3.17-3.16 
(d, 1H), 2.13 (s, 4H), 1.94-1.87 (m, 6H), 0.89-0.80 (m, 12H); 13C NMR 
(DMSO-d6, δ=39.52 ppm, 126 MHz): δ 170.35, 156.77, 150.39, 149.67, 
147.82, 137.76, 135.00, 130.43, 125.64, 123.38, 121.04, 117.89, 116.19, 
113.71, 113.19, 57.99, 54.18, 51.44, 48.61, 46.79, 30.96, 30.87, 29.84, 
24.26, 18.51; HRMS (ESI) m/z: Anal. calcd. for [M+H]+ C40H51N8O10S: 
835.3443; found 835.3445. 
 
Methyl ((R)-2-((S)-2-((3-hydroxyphenyl)carbamoyl)pyrroli-din-1-yl)-2-
oxo-1-phenylethyl)carbamate (43a). Yield (839 mg, 79%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 400 MHz): δ 10.00/9.86/9.73 (3 s, 
0.20H+0.14H+0.72H), 9.37 (s, 1H), 7.98-7.97/7.71-7.69/7.55-7.52 
(d/d/m, 0.34H+0.86H+0.41H), 7.42-7.30 (m, 4H), 7.20/7.15-7.13 (s/t, 
0.70H+0.39H), 7.09-7.05 (t, 1H), 7.00-6.85/6.87-6.85 (2 d, 
0.73H+0.19H), 6.47-6.45 (d, 1H), 5.51-5.49/5.33-5.31/4.92-4.89 (3 d, 
0.74H+0.21H+0.19H), 4.39-4.37 (t, 1H), 3.81 (s, 1H), 3.54 (s, 3H), 3.21-
3.15 (q, 1H), 2.33-1.77 (m, 4H); 13C NMR (DMSO-d6, δ=39.52 ppm, 126 
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MHz): δ 170.09, 168.34, 157.61, 156.07, 140.03, 137.20, 129.31, 128.61, 
128.04, 110.42, 110.04, 106.48, 60.69, 56.71, 51.64, 46.95, 29.34, 24.25; 




yl)-3-methyl-1-oxobutan-2-yl)carbamate (43b). Yield (455 mg, 64 %); 1H 
NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): δ 11.67 (app br s, 1H), 9.44 (app br 
s, 1H), 7.36-7.25 (m, 2H), 7.17-6.86 (m, 3H), 6.56 (s, 1H), 5.24-5.23/5.08-5.07 
(2 d, 0.13H+0.81H), 4.08-4.05 (t, 1H), 3.80-3.76 (d, 2H), 3.54-3.44 (app s, 3H), 
2.27-2.08 (m, 2H), 2.01-1.86 (m, 3H), 0.89-0.84 (q, 6H); 13C NMR (DMSO-d6, 
δ=39.52 ppm, 126 MHz): δ 170.43, 157.61, 156.85, 129.33, 115.06, 113.06, 
111.10, 58.05, 57.54, 55.19, 54.25, 51.47, 46.87, 30.92, 29.88, 24.31, 19.04, 




pyrrolidine-2-carboxamido)phenyl sulfurofluoridate (43c). A mixture 
of Methyl ((R)-2-((S)-2-((3-hydroxyphenyl)carbamoyl)-pyrrolidin-1-yl)-
2-oxo-1-phenylethyl)carbamate (276 mg, 0.695 mmol) and N,N-
Diisopropylethylamine (363 L, 2.09 mmol) in CH2Cl2 (10 mL) was 
stirred under sulfuryl fluoride at room temperature for 5 h. The mixture 
was then poured in 1 N aq HCl solution and extracted with CH2Cl2. The 
organic layer dried over magnesium sulfate, filtered, and concentrated in 
vacuo. Without any purification, the residue was obtained as a white oil; 
Yield (255 mg, 76%); 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 
10.58/10.51/10.41/10.34 (4 s, 0.02H+0.23H+0.11H+0.53H), 7.99-7.86 
(m, 1H), 7.74-7.66 (m, 1H), 7.63-7.59 (t, 1H), 7.56-7.52 (t, 1H), 7.42-
7.41 (d, 2H), 7.38-7.35 (t, 2H), 7.34-7.32 (m, 1H), 7.29-7.24/7.06-
7.05/6.72-6.70 (m/d/d, 0.88H+0.28H+0.06H), 5.52-5.47/5.35-5.33/4.90-
4.88 (m/d/d, 0.88H+0.08H+0.08H), 4.50-4.38 (m, 1H), 3.83-3.62 (m, 1H), 
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3.54 (s, 3H), 3.20-3.10 (m, 1H), 2.29-1.78 (m, 4H); 13C NMR (DMSO-d6, 
δ=39.52 ppm, 100 MHz): δ 170.95, 168.40, 156.06, 149.63, 140.92, 
137.15, 130.98, 128.58, 128.39, 128.02, 119.34, 115.34, 111.06, 60.69, 
56.66, 51.59, 46.94, 29.17, 24.28; 19F NMR (DMSO-d6, 376 MHz,): 
38.64; HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ C21H22FN3NaO7S: 




(43d). A mixture of Methyl ((S)-1-((S)-2-(5-(3-hydroxyphenyl)-1H-
imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
(158 mg, 0.409 mmol), tert-Butyldimethylsilyl chloride (123 mg, 0.817 
mmol), Imidazole (139 mg, 2.04 mmol) in CH2Cl2 (10 mL) was stirred at 
room temperature for 4 h. The mixture was then poured in H2O and 
extracted with CH2Cl2. The organic layer dried over magnesium sulfate, 
and then was purified by the column chromatography (n-hexane / ethyl 
acetate). The residue was obtained as sticky white oil; Yield (187 mg, 
91%);  1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 
12.12/12.03/11.77 (3 s, 0.16H+0.09H+0.68H), 7.44-7.06 (m, 5H), 6.69-
6.60 (m, 1H), 5.06-5.05 (d, 1H), 4.08-4.04 (t, 1H), 3.79 (s, 2H), 3.53 (s, 
3H), 2.16-2.07 (m, 2H), 1.96-1.89 (m, 3H), 0.96 (s, 9H), 0.92-0.90 (d, 
2H), 0.88-0.82 (q, 4H), 0.18 (s, 6H); 13C NMR (DMSO-d6, δ=39.52 ppm, 
126 MHz): δ 170.30, 156.78, 155.24, 149.15, 138.83, 136.71, 129.36, 
117.49, 117.08, 115.60, 112.41, 57.96, 54.21, 51.42, 46.80, 31.01, 29.84, 
25.61, 24.13, 19.01, 18.56, 17.96; HRMS (ESI) m/z: Anal. calcd. For 








phenylacetyl)pyrrolidine-2-carboxamido)phenyl sulfurofluoridate (88.9 
mg, 0.178 mmol), Methyl ((S)-1-((S)-2-(5-(3-((tert-
butyldimethylsilyl)oxy)phenyl)-1H-imidazol-2-yl)pyrro-lidin-1-yl)-3-
methyl-1-oxobutan-2-yl)carbamate (102 mg, 0.213 mmol) and DBU 
(34.5 L, 0.230 mmol) in DMF (10 mL) was stirred at 50℃ for 12 h. The 
mixture was then poured in water and extracted with CH2Cl2. The organic 
layer dried over magnesium sulfate, and then crude product was purified 
by the column chromatography (n-hexane / ethyl acetate). The residue 
was obtained as white solid; Yield (97.1 mg, 65%); 1H NMR (DMSO-d6, 
δ=2.5 ppm, 500 MHz): δ  11.95 (s, 1H), 10.46/10.28 (2 s, 0.56H+0.31H), 
7.92-7.88 (d, 1H), 7.82-7.72 (m, 2H), 7.66-7.63 (m, 1H), 7.61-7.58 (t, 1H), 
7.49-7.46 (t, 1H), 7.41-7.40 (d, 2H), 7.38-7.35 (t, 1H), 7.33-7.25 (m, 3H), 
7.22-7.20 (d, 1H), 7.12-7.08 (t, 1H), 7.03-6.63 (m, 1H), 5.51-5.46/5.32-
5.31/5.22-5.20 (m/d/d, 0.76H+0.06H+0.11H), 5.07-5.04/4.90-4.88 (m/d, 
0.80H+0.05H), 4.49-4.37 (m, 1H), 4.06-4.03 (t, 1H), 3.79-3.65 (m, 2H), 
3.53 (s, 6H), 3.45-3.39 (m, 1H), 3.23-3.08 (m, 1H), 2.19-2.08 (m, 2H), 
1.95-1.94 (d, 2H), 1.92-1.85 (m, 2H), 1.65-1.55 (m, 3H), 1.23 (s, 0.81H) 
0.87-0.81 (m, 6H); 13C NMR (DMSO-d6, δ=39.52 ppm, 126 MHz): δ 
170.76, 170.34, 168.34, 168.15, 156.77, 156.29, 150.38, 149.89, 140.83, 
136.78, 130.62, 130.49, 128.56, 128.33, 128.00, 127.75, 123.42, 118.12, 
116.18, 115.30, 111.13, 60.59, 57.96, 56.60, 54.15, 51.41, 46.79, 30.96, 
29.83, 29.20, 24.69, 24.19, 18.83, 18.48; HRMS (ESI) m/z: Anal. calcd. 
for [M+H]+ C41H48N7O11S: 846.3127; found 846.3129. 
 
Methyl ((R)-2-((S)-2-((3-((tert-butyldimethylsilyl)oxy)-phe-nyl)carba-
moyl)pyrrolidin-1-yl)-2-oxo-1-phenylethyl)-carbamate (44a). A mixture 
of methyl ((R)-2-((S)-2-((3-Hydroxyphenyl)carba-moyl)pyrrolidin-1-yl)-
2-oxo-1-phenyl-ethyl)carbamate (51.1 mg, 0.129 mmol), tert-
Butyldimethylsilyl chloride (29.1 mg, 0.193 mmol), imidazole (26.3 mg, 
0.0263 mmol) in CH2Cl2 (10 mL) was stirred at room temperature for 4 
h. The mixture was then poured in H2O and extracted with CH2Cl2. The 
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organic layer dried over magnesium sulfate, and then was purified by the 
column chromatography (n-hexane / ethyl acetate). The residue was 
obtained as sticky white oil; Yield (53.5 mg, 81%); 1H NMR (DMSO-d6, 
δ=2.5 ppm, 500 MHz): δ 10.08/9.82 (2 s, 0.18H+0.81H), 7.97-7.96/7.71-
7.69 (2 d, 0.13H+0.81H), 7.41-7.31 (m, 4H), 7.26 (s, 1H), 7.17-6.97 (m, 
2H), 6.54 (s, 1H), 5.50-5.48/5.32-5.30/4.90-4.88 (3 d, 
0.84H+0.14H+0.13H), 4.37 (s, 1H), 3.81 (s, 1H), 3.53 (s, 3H), 3.18-3.16 
(d, 1H), 1.98-1.77 (m, 4H), 0.96-0.95 (app s, 9H), 0.20-0.19 (app s, 6H); 
13C NMR (DMSO-d6, δ=39.52 ppm, 126 MHz): δ 170.21, 168.29, 156.01, 
155.28, 140.18, 137.15, 129.46, 128.56, 128.00, 127.70, 114.58, 112.27, 
110.74, 60.67, 56.66, 51.58, 46.90, 29.26, 25.54, 24.22, 17.89, -4.50; 





moyl)pyrrolidine-1-carboxylate (44b). A mixture of Methyl ((R)-2-((S)-2-((3-
((tert-butyldimethylsilyl)-oxy)phenyl)carbamoyl)pyrrolidin-1-yl)-2-oxo-1-
phenylethyl)-carbamate (602 mg, 1.18 mmol), tert-Butyl (S)-2-((3-
((fluorosulfonyl)oxy)phenyl)carbamoyl)pyrrolidine-1-carboxylate (914 mg, 
0.235 mmol) and DBU (35.2 L, 0.235 mmol) in DMF (10 mL) was stirred at 
50℃ for 12 h. The mixture was then poured in 1 N aq HCl solution and 
extracted with CH2Cl2. The organic layer dried over magnesium sulfate, and 
then was purified by the column chromatography (n-hexane / ethyl acetate). 
The residue was obtained as white solid; Yield (676 mg, 75%); 1H NMR 
(DMSO-d6, δ=2.5 ppm, 500 MHz): δ 10.44-10.25 (m, 2H), 7.94-7.90 (t, 2H), 
7.73-7.71 (d, 1H), 7.66-7.57 (m, 2H), 7.49-7.45 (m, 2H), 7.42-7.40 (d, 2H), 
7.38-7.24 (m, 3H), 7.14-7.04 (m, 2H), 5.52-5.47/5.35-5.33/4.91-4.89 (m/d/d, 
0.83H+0.10H+0.09H), 4.51-4.38 (m, 1H), 4.27-4.25/4.20-4.17 (d/q, 
0.35H+0.64H), 4.14-4.10 (q, 1H), 3.82 (s, 1H), 3.53 (s, 3H), 3.46-3.42 (m, 1H), 
3.37-3.34 (m, 1H) 3.19-3.17 (d, 3H), 2.24-2.13 (m, 1H), 2.05-1.78 (m, 7H), 
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1.39-1.24 (app s, 9H); 13C NMR (DMSO-d6, δ=39.52 ppm, 126 MHz): δ 172.03, 
170.78, 168.35, 153.06, 149.85, 140.74, 130.66, 128.57, 128.34, 128.00, 118.40, 
115.34, 111.40, 78.60, 60.46, 56.64, 51.61, 46.56, 30.91, 29.19, 27.89, 24.27, 






carboxamido)phenyl) sulfate (44, BMK-21057). A mixture of tert-Butyl 
(S)-2-((3-(((3-((S)-1-((R)-2-((methoxycarbonyl)amino)-2-
phenylacetyl)pyrrolidine-2-carboxamido)phenoxy)sulfonyl)-
oxy)phenyl)carbamoyl)pyrrolidine-1-carboxylate (426 mg, 0.557 mmol) 
in CF3CO2H (5 mL) / CH2Cl2 (5 mL) was stirred at room temperature for 
30 m. The volatile component was removed in vacuo, 1-Ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (139 mg, 0.724 mmol), 
Hydroxybenzotriazole hydrate (97.8 mg, 0.724 mmol), 5-[(3aS,4S,6aR)-
2-Oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoic acid (163 mg, 
0.668 mmol) were added in batches over 4 min to a solution of N,N-
Diisopropylethylamine (485 L, 2.78 mmol) in CH2Cl2 (10 mL) and the 
reaction mixture stirred at room temperature for overnight. The mixture 
was then poured in 1 N aq HCl solution and extracted with CH2Cl2. The 
organic layer dried over magnesium sulfate, and then was purified by the 
column chromatography (n-Hexane / EA). The residue was obtained as 
white solid; Yield (479 mg, 96 %); 1H NMR (DMSO-d6, δ=2.5 ppm, 500 
MHz): δ 10.52/10.45/10.36/10.27 (4 s, 0.38H+0.53H+0.89H+0.31H), 
7.91-7.84 (m, 2H), 7.75-7.58 (m, 3H), 7.50-7.44 (m, 2H), 7.41-7.29 (m, 
5H), 7.23-7.04 (m, 2H), 6.44 (s, 1H), 6.39-6.34 (t, 1H), 5.50-5.45/5.32-
5.30/5.21-5.19/5.09/4.88-4.87 (q/d/d/s/d, 
0.84H+0.07H+0.05H+0.03H+0.10H), 4.54-4.25 (m, 4H), 4.13-4.07 (m, 
1H), 3.81-3.56 (m, 3H), 3.53 (s, 3H), 3.20-3.00 (m, 2H), 2.82-2.74 (m, 
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1H), 2.58-2.56 (d, 1H), 2.33-2.26 (m, 2H), 2.17-2.12 (m, 1H), 2.17-1.96 
(m, 2H), 1.91-1.81 (m, 5H), 1.64-1.58 (m, 1H), 1.51-1.44 (m, 3H), 1.40-
1.33 (m, 2H), 1.23 (s, 1H); 13C NMR (DMSO-d6, δ=39.52 ppm, 126 MHz): 
δ 171.41, 170.81, 168.35, 162.71, 156.31, 149.87, 140.88, 136.79, 130.62, 
128.57, 128.33, 128.00, 118.22, 115.23, 113.71, 111.17, 61.05, 60.61, 
60.01, 59.19, 56.61, 55.47, 51.53, 46.93, 33.35, 29.47, 29.20, 28.20, 24.46, 
24.24; HRMS (ESI) m/z: Anal. calcd. for [M+Na]+ C42H49N7NaO11S2: 




Measurement of the anti-HCV activities of compounds using HCVcc 
 
Cell line and cell culture 
Huh 7.5.1 cells were grown in Dulbecco’s Modified Eagle’s medium 
(DMEM; Gibco) containing antibiotics (100 U/mL penicillin, 10 g/mL 
streptomycin) and 10% heat-inactivated fetal bovine serum (ΔFBS; Hyclone) 
at 37°C in a humidified 6.0% CO2 incubator. 
 
Virus production 
In vitro transcribed RNA of JFH5a-Rluc-ad34, which is a derivative of JFH1 
with adaptive mutations in the E2 and p7 regions,[74] was transfected into 
Huh7.5.1 cells by electroporation. JFH5a-Rluc-ad34 virus contains a reporter 
Renilla luciferase (Rluc) for convenient virus proliferation assay.[74] HCV-
containing cell culture media were collected 3~5 days after electroporation and 
filtered through a 0.45 M pore size filter. 
 
Antiviral activity test with infectious HCV particles  
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Huh 7.5.1 cells were inoculated with a JFH5a-Rluc-ad34 virus stock and 
cultivated for 3 h. At 3 h after the virus inoculation, HCV-infected Huh7.5.1 
cells were cultured with media containing serially diluted compounds. At 3 days 
after the chemical treatment, the cells were harvested and their luciferase 
activities were measured using a Renilla luciferase assay system (Promega) 
according to the manufacturer’s direction. Finally, the luciferase activities were 
normalized to those obtained from mock-treated cells. 
 
Measurement of anti-HCV activities of compounds using HCV 
replicon  
 
Cell line and cell culture 
Huh 7.5.1 cells containing a bicistronic HCV replicon NK5.1-Gluc cell line 
(genotype 1b) were employed for the interrogation of the anti-HCV activities 
of the compounds (Figure 7). The first open reading frame (ORF) of the 
replicon contains the Gaussia luciferase gene fused with foot-and-mouth 
disease virus (FMDV) 2a gene and the neomycin phosphotransferase gene, and 
the second ORF contains HCV nonstructural genes NS3-5. The replicon-
containing cells were cultivated under the same conditions as described above 
in presence of an additional antibiotic G418 (0.5 mg/ml, Calbiochem). 
 
 
Figure 7. The structure of replicon NK5.1-Gluc. 
 
Antiviral activity assay test with HCV replicon 
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Huh 7.5.1 cells containing HCV replicon (NK5.1-Gluc) were planted on a 12-
well plate (Figure 7). At 16 h after cultivation, the replicon containing 
NK/R2AN-containing cells were incubated with media containing serially 
diluted compounds for 3 days. After the chemical treatment, the cell culture 
media were collected and luciferase activities were measured through the use 
of the Renilla luciferase assay system (Promega) according to manufacturer’s 
direction, and then normalized to those obtained from mock-treated cells. 
 
hERG ligand binding assay[75] 
The hERG ligand binding assay was performed by using the hERG 
Fluorescence Polarization Assay Kit (Cat No. PV5365), containing predictorTM 
hERG tracer red, predictorTM hERG membrane, and predictorTM hERG FP 
assay buffer. Test compounds (10 M) and positive control (Astemizole) were 
added to the 384-well plate (5 L each; low-volume polystyrene plate, corning 
#3677). Then, membrane (10 L) and tracer (5 L) were added to each plate 
through the use of a multi-pipette (Multi 16 channel pipette type 5–50 L, 
Thermo). The plate was then covered with aluminum foil and was kept for 2–3 
h at room temperature. Lastly, the fluorescence polarization of the hERG red 
tracer was measured using a microplate reader (molecular devices, SpectraMax 
M5e, excitation (540 nm) emission (585 nm) filters). 
 
Plasma stability measurement 
Rat plasma (297 L) was pre-incubated for 5 min at 37°C in a water bath. The 
plasma and 100 M test compounds (3.0 L) were agitated through the use of 
a vortex, and incubated for 37°C in a water bath. Then the mixture was sampled 
multiple times (0, 15, 30, 60, and 120 min). A mixture of crude sample (50 L) 
and acetonitrile (100 L) was then treated by centrifugation at 10,000 rpm for 






The Ames test was carried out with the Maron’s method using Ames MPF™ 
98/100 Mutagenicity Assay kit. Histidine-dependent strains (TA98, and TA100) 
of Salmonella typhimurium were treated with inhibitors BMK-21014 and 
BMK-21025 at 1,000 g/plate and bis(4-aminophenyl) sulfate at 5,000 g/plate 
and with positive controls (2-nitrofluorene, sodium azide, and benzo[a]pyrene). 
The number of colonies was counted three times for each medium to provide 
acceptable data for statistical analysis.  
 
Observation of the effects of co-treatment of two compounds  
Huh 7.5.1 cells containing the HCV replicon (NK5.1-Gluc) were plated on a 
12-well plate (5 x 104 cells per well). At 16 h after cultivation, the replicon 
containing cells were treated with inhibitors alone or with mixtures of inhibitors 
and sofosbuvir at serially diluted concentrations. At 3 days after treatment, 
Gaussia luciferase activities were measured using the Renilla luciferase assay 
system (Promega) according to the manufacturer’s direction, and then 
normalized to those obtained from mock-treated cells. Combination index was 
calculated by using Compusyn Freeware Program (ComboSyn, Inc). 
 
Molecular docking 
The X-ray structure of 3FQQ and NMR structure of 1R7G were retrieved from 
the protein data bank (PDB) and prepared via homology modeling with 
Discovery Studio Client. The default ligand settings were used to prepare all 
tautomers, and further energy minimized. The inhibitors were then docked into 






Figure 8. Representative 1H NMR (400 MHz, DMSO-d6) Analysis of 
Fosylation and SuFEx. Reaction illustrated a Starting Material (red) and 
fosylated compound (blue) and SuFEx product (black). 
 
 
Figure 9. Representative 19F NMR (400 MHz, DMSO-d6) Analysis of 
Fosylation and SuFEx. Reaction illustrated a Starting Material (red) and 




Figure 10. Representative 13C NMR (400 MHz, DMSO-d6) Analysis of 
Fosylation and SuFEx. Reaction illustrated a Starting Material (red) and 







Figure 11. 2D-interaction docking model of compounds in an NS5A 
dimer model. (A) BMK-21007, (B) BMK-21014, (C) BMK-21022, and 
(D) BMK-21040 inside NS5A dimer model (3FQQ). Various interactions 
are depicted by different color legends. Inhibitors are shown by line, 
interacting residues by colored sphere, and interactions by dash lines. 
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Figure 12. Superposed model of inhibitors inside NS5A dimer model 
(3FQQ). Daclatasvir, BMK-21007, and BMK-21022 shown by orange, 
blue, and red, respectively. 
91 
 
Figure 13. Superposed model of inhibitors inside NS5A dimer model 









Development of effective treatments 
for hepatitis C genetic mutations 










Figure 14. Structure of BMK-21001 and Ames results of metabolite. (a) 
Sturucture of BMK-21001 and EC50 for genotypes of HCV. (b) Ames test 
results of metabolite of BMK-21001. Orange line means fold induction over 
the baseline. If fold induction value is more than 3, it is regarded as mutagen. 
 
Based on chemical structure of the BMK-20113, we had optimized the NS5A 
inhibitor by introducing the substituted benzidine derivatives. When we tested 
the anti-viral activities of compounds, meta-substitution of the benzidine 
prolinamides made the inhibitors highly potent HCV inhibitors. In addition, 
previously reported NS5A inhibitors containing a fluorenyl core structure have 
the positive results of various genotypes for HCV. Therefore, we envisioned 
that the activity of m-,m-connected benzidine like fluorene derivatives would 
exhibit high potency in the antiviral assays. Among them, BMK-21001 which 
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has 9,9-difluorofluorene and prolinamide skeleton structure has picomolar 
range of EC50 value at wild type and L31V resistance mutant as shown in the 
figure 14. However, that inhibitor could not fully overcome major daclatasvir 
resistance mutant such as Y93H and double mutant (L31V+Y93H).[19, 53] 
Moreover,  the 9,9-difluoro-9H-fluorene-2,7-diamine, which is metabolite 
compound of BMK-21001, showed a positive result in the Ames test. the 
fluorene structures have generally genotoxicity like 2-nitrofluorene, which are 
used for Ames positive control. However, we were convinced that fluorene 
must have been good pharmacophore as the NS5A inhibitor. So, we screened 
the 2,7-diaminofluorene derivatives to find the Ames negative fluorene 
structure. Among the fluorene derivatives, the compounds containing an alkyl 
chain that has 4 or 5 carbon atoms at the 9-position in fluorene were shown the 
Ames positive only at 5 mM or more (data not shown). 
 
 
Figure 15. Design strategy of new NS5A inhibitors. We tested inhibition effect 
by modifying X, Y and Z site in BMK-21001. 
 
Based on these results, we further developed NS5A inhibitors based upon a 
9,9-dibutyl or 9,9-dipentyl fluorene prolinamide skeleton that have high 
inhibition effect on pan-genotype HCV and genotype 1b daclatasvir resistance 
mutant (figure 15). 
 
2. Results and Discussion 
 
NS5A inhibitory activities of new inhibitors depending upon the 
substituted fluorine core structure  
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To determine structure activity relationship (SAR) of new anti-NS5A 
inhibitors, we sequentially modified the NS5A inhibitor structure at the 9 
position of fluorenyl core structure as can be seen in Figure 14. We modified 
the length of the 9,9-dialkyl substitution of the fluorene core (R) to determine 
the replication inhibitory activities on pan-genotype and daclatasvir resistant 
mutant HCV such as L31V, Y93H and L31V+Y93H. To evaluate the 50% of 
effective concentration (EC50) of modified compounds, we used HCV cell 
culture system (HCVcc) and HCV replicon system.[76, 77] For measuring EC50 
in HCVcc system (GT 2a), we made a modified JC1 clone (JC1-Gluc) 
containing Gaussia Luciferase gene (Gluc) between P7 and NS2 region as 
previously reported.[77] Using the JC1-Gluc system, we infected this virus to 
Huh 7.5.1 cells for 4 hrs. After 4 hrs, huh 7.5.1 cells were incubated with 
Dulbecco’s Modified Eagle Medium (DMEM) containing serially diluted 
inhibitor and waited until 72 hrs. After 72 hrs, the cell supernatant was 
harvested for measuring the Gaussia luciferase activity. To determine the 
inhibitory effect of the compounds on HCV 1b and 3a replication, we used HCV 





Figure 16. Schematic structure of replicons. (a) genotype 1b (NK5.1-Gluc) (b) 
genotype 2a (JC1-Gluc) (c) genotype 3a (S52-Feo) 
 
The replicon system contains the HCV non-structured proteins (NS3-NS5B) 
which are bicistronically co-translated with luciferase gene fused with 
neomycin phosphotransferase as described in material and method (Figure 15). 
The replicon system is capable of viral RNA replication in the cell. Procedure 
for making the replicon cell line is described in material and methods. HCV 
bicistronic RNA-containing cell lines were incubated in the presence of 
inhibitors for 72 hrs. After 72hrs later, cultivated cells or supernatants were 
harvested for measuring the luciferase activity in genotypes 1b and 3a, 





































n-Pent 3.30 5.90 7.30 2.70 2.30 47.8 
aResults from three independent experiments with duplicate. EC50, Effective 
concentration 50%. 
bDaclatasvir resistance mutant for genotype 1b, D.M., Double mutant 
(L31V+Y93H). 
 
Based on Figure 15 structure, we fixed the linker and cap region in compounds 
as phenylglycine and carbamate moiety, respectively, and changed only the 
carbon length of the substituents on the fluorene core (R at Figure 15) as 
described in Table 11. The compound 45, which has ethyl residue substituent 
in fluorene core, showed EC50 of 0.071 nM and 0.336 nM in genotype 1b and 
3a, respectively. However, the compound 48, which has a longer fluorene core 
length than compound 45, showed single digit pM range EC50 values in 
genotype 1b and 3a HCV. The assay result indicated that inhibition effect was 
related to fluorene core length on genotype 1 and 3 HCV. Also increasing the 
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alkyl length of fluorene core has a role for inhibition against 1b and 3a HCV, 
not 2a. 
Next, to determine the inhibition effect of the above-mentioned compounds 
on resistance mutant HCV, we transfected resistance mutant HCV RNA to 
Huh7.5.1 as described in Experimental section. Table 11 indicates the EC50 
value of the compounds against daclatasvir resistance mutant HCV. By 
comparing compounds 45 to 48, we found that length of the alkyl group on the 
fluorene core plays a key role for inhibiting the L31V resistance mutant. As a 
result, these data suggest that we not only developed compounds having a good 
inhibitory effect on wild type HCV by modifying the fluorene core, but also 
confirmed the role of the alkyl group length on the fluorene core for the 





Proline structure dependent Y93H resistance mutant effect in 
genotype 1b HCV 
 
Table 12. The EC50 values of inhibitors containing 9,9-dibutylfluorene and 
pyrrolidine derivatives (pM)a 
 
















































29.6 3.50 133 25.2 29.0 0.058 
aResults from three independent experiments with duplicate. EC50, Effective 
concentration 50% 




Among our candidate compounds, compounds containing 9,9-dibutylfluorene 
or 9,9-dipentylfluorene core structure (compound 47 and 48, respectively) 
showed remarkable inhibitory effects against L31V resistance mutant. In this 
regard, we fixed core residue with 9,9-dibutylfluorene or 9,9-dipentylfluorene 
structure to determine the effect of the modification on the L-proline residue (Y, 





Table 13. The EC50 values of inhibitors containing 9,9-dipentylfluorene and 
pyrrolidine derivatives (pM)a 
 





































3.00 19,400 435 0.60 4.60 0.051 
Daclatasvir 
(reference) 
7.00 28.0 1,000 410 620 0.781 
aResults from three independent experiments with duplicate. EC50, Effective 
concentration 50% 
bDaclatasvir resistance mutant for genotype 1b, D.M., Double mutant 
(L31V+Y93H) 
 
Prior to observing the inhibition effect of the compounds on daclatasvir 
resistance mutant HCV, we first ascertained whether the inhibitors possessing 
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the modified L-proline structure have anti-HCV effect against wild type HCV 
and they exhibited picomolar EC50 values in genotype 1b and 3a HCV, but not 
2a HCV (Table 12 and 13). 
Next, we measured the inhibition effect of proline modified compounds 
against daclatasvir resistance mutant HCV. Interestingly, when we compared 
the compound series from compound 47 to 59, it was observed that the 
inhibitory effect on Y93H resistance mutant varied depending on the proline 
structure. In particular, by comparing EC50 values between proline modified 
compounds and non-modified compounds (47 and 48, respectively), we learned 
that compounds with 4-oxo-L-proline, 4-spiro cyclic ketal-L-proline or 4-
hydroxyl-L-proline structure are related to the inhibition of Y93H and double 
mutant, L31V and Y93H (Table 12 and 13). Particularly, 4-spiro cyclic ketal-L-
proline (53 and 59) or 4-hydroxyl-L-proline 54 showed single or double digit 
EC50 values at Y93H or double mutant resistance mutant HCV. Consequently, 
these results suggest that L-Proline (Y and Z in Figure 15) residue of compound 
served to inhibit HCV replication by binding of NS5A Y93 or H93 residue 
together with fluorene core residue. 
 
Structure dependent colony formation assay on replicon HCV 
HCV RNA encodes an error-prone RNA dependent RNA polymerase (RdRp) 
NS5B, which has low fidelity in RNA proofreading process.[14] For this reason, 
the media containing NS5A inhibitor can eliminate HCV in the cell since 
generating mutation by NS5A inhibitor cannot be revised during replication, 
which results in the selection of HCV RNA resistance cells against the NS5A 
inhibitors. As described before, HCV replicon system has two IRES elements 
that allow the co-translation of non-structural protein and Neomycin 
phosphotransferase bicistronically. If the HCV RNA survive by accruing 
resistance mutant, it will translate neomycin phosphotransferase and as results, 
cells with mutant RNA can grow media containing G418 condition. Thus, cell 
containing HCV RNA, which get resistance mutation, can grow by compound 
treatment condition and eventually can be observed through colony forming. 
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Moreover, by comparing rate of colony formation, we can infer the compound 
resistance barrier on the level of mutant colony formation or elimination of 
HCV replicon cell.[21] 
To compare the rate of colony formation caused by compound structure, each 
of compounds was treated with the same concentration for 5 days to genotype 
1b or 3a replicon cell in the absence of G418. After 5 days, the compounds 
inoculated cells were split with two plate, one plate kept treating compounds 
without G418 and the other plate maintained in presence of 1mg/ml G418 
without treating compounds for 14 days for colony forming. This procedure 
was repeated every 5 days and proceeded for 15 days. The selected cells by 
G418 can display a change in the colony formation rate depending on the 
treatment time, compound concentration and structure, so these results 











Figure 18. Colony formation assay on S52 replicon HCV (GT-3a) 
 
Using this procedure, we incubated compounds on replicon cell for long 
periods to see the resistance barrier depending on compound structure. The 
colony formation results showed that compound 47 and 48, which have L-
proline residue, have low inhibition effect for emergency of colony formation. 
And also, 53, 54 and 59, which modified L-proline residue as 4-spiro-ketal 
proline or 4-hydroxyl-L-proline, more efficiently inhibited generating 
resistance colony on genotype 1b replicon (Figure 17). Especially, 54 showed 
high elimination level for forming resistance colony than 47 or 48 in spite of 
the high EC50 value on genotype 3a replicon cell. So, the 54 has a high 
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resistance barrier on both HCV genotype (Figure 17 and 18). As a result, this 
experiment indicated that the resistance barriers for each compound and also 
modification of L-proline moiety well inhibit the production of colonies 
containing resistance mutants. 
 
Humanized mice liver test in Genotype 3a HCV  
In-vitro assay results indicated that modified compounds have high inhibition 
effect on 1b and 3a replicon cell. Even though genotype 1b is most prevalent 
genotype, many of commercial drugs including daclatasvir already targeted 1b 
HCV and those have high SVR rated.[78] In this regard, we chose genotype 3a 
HCV for in-vivo efficacy test since occurring of genotype 3a resistance mutant 
still has a problem to decrease SVR rate by DAA’s.[23] To observe genotype 3a 
HCV inhibition effect in in-vivo system, we used humanized liver mice that 
human hepatocytes (h-heps) transplanted into the spleen of urokinase-type 
plasminogen activator (uPA) / severe combined immunodeficient (SCID)-
mice.[24, 32] By transplanting, the level of Human-Albumin (h-Alb) was 
monitored for 8 weeks to confirm the regeneration of human hepatocytes (h-
heps) with mice liver. After 8 weeks, mice well expressed the h-Alb were 
inoculated with genotype 3a HCV. Then HCV RNA level was confirmed by 





















P.O. 8 21893.8 1374.5 4.6 39.3 




P.O. 20 256.5 142.0 2.9 0.6 
I.V. 5 10873.8 16400 4.4  
aValues are mean and standard deviation; p.o., oral; i.v., intravenous; AUClast, 
Area under the plasma semi logarithmic concentration versus time curve from 
the time of dosing to the last measurable concentration; Cmax, maximum 
concentration of the drug; t1/2, half-life; F(%), oral bioavailability. 
bPK experiments were conducted using male mice (n = 3). 
cVehicle: 5% DMSO, 10% Solutol, 85% HPBCD (20%, w/v). 
dVehicle: 10% Dimethylacetamide, 10% Polysorbate 80, 80% HPBCD (20%, 
w/v) 
 
Even though compound 54 has highest resistance barrier, but it showed poor 
pharmacokinetics profile on oral administration (Table 14). On the other hand, 
compound 47 showed good pharmacokinetics profile on oral administration. So, 
we chose compound 47 to determine the inhibition effect against genotype 3a 





Figure 19. Genotype 3a HCV inoculated to humanized mice. HCV RNA was 
determined through RT-PCR in mouse serum after inoculated with HCV 
genoytype 3a. (a) compound 47 was treated for 2 weeks with 10 mg/kg. (b) 50 
mg/kg. 
 
The compound 47 had well inhibited HCV replication for 3 days at 10 mg/kg 
or 50 mg/kg treatment concentration, but HCV RNA level rebounded after 3 
day despite of continuation of the compound treatment (Figure 19). Previous 
reports already noted that mono-administration of daclatasvir resulted in virus 
recovery due to low resistance barrier of NS5A inhibitor in genotype 1a or 1b 
HCV infected patient serum.[79] So these results suggests that mono-treatment 
of NS5A inhibitor has a limitation to inhibit HCV completely since the 
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resistance mutants of genotype 3a HCV could be generated. In spite of having 
some limitation, our results suggests a possibility that compound 47 can inhibit 
genotype 3a HCV well in human liver. 
 
Combination test with NS3-4A protease inhibitor 
The structure modification of anti-NS5A compound brought high inhibition 
effect on wild type HCV and daclatasvir resistance mutant HCV. Among them, 
the compound 47 has a good inhibition effect on humanized liver mice infected 
with genotype 3a HCV. However, the results of humanized liver mice 
additionally indicated the limitation of NS5A mono-treatment since HCV RNA 
level was rebounded after 3 days in mice serum. To overcome the limitation of 
mono-treatment, we referred to guideline of HCV therapy that NS5A inhibitors 
should be co-treated with other DAA’s such as NS3/4A protease inhibitors or 
NS5B inhibitors.[79, 80] To determine the combination effect, we selected several 
NS5A inhibitors (compound 47, 53, 59 and 54), which called key compounds, 
showing high inhibition effect on genotype 1b and 3a and daclatasvir resistance 
mutant HCV. To evaluate combination effect of key compounds with 
representative DAA’s, such as grazoprevir (NS3-4A inhibitor), we used the 
Chou-Talalay method.[73] Compound 47, 53, 59 and 54 were co-treated with 
constant ratio of grazoprevir to genotype 1b or 3a replicon cell, respectively. 
And then, we calculated relative inhibition ratio by 0.1% DMSO treated cell. 






Table 15. Combination index of NS5A inhibitors and grazoprevir.a,b 
Compound 











0.8 1.1 0.65 0.76 
53 
(BMK-21069) 
0.9 1.13 0.54 0.65 
59 
(BMK-21067) 
0.6 1.0 0.91 0.93 
54 
(BMK-21075) 
0.7 0.8 1.0 0.82 
aCI > 1, antagonism effect; CI < 1, synergistic effect; CI ~ 1, additive effect 
bNS3-4A Inhibitor 
cEC50 CI value, Effective Concentration 50 percent Combination Index value 
dEC70 CI value, Effective Concentration 75 percent Combination Index value 
 
Combination index value of key compounds was below 1 point at 50% and 
75% effective concentration. That combination index value suggests that key 
compounds have synergic or additive effect with other DAA’s at each effective 








Figure 20. Colony formation assay for combination with grazoprevir. (a) 




Previously, we showed the resistance barrier of key compounds as a colony 
formation assay in genotype 1b or 3a HCV replicon cell. Using this method, 
compound 47 or 54 was treated with grazoprevir (about EC90 concentration) to 
detect the combination effect on the development of resistance mutant and we 
observed that resistance colonies were virtually eliminated by concomitant 
treatment with grazoprevir, which mean that the limitation of NS5A inhibitor 
mono-therapy could be overcome by concomitant with other DAA’s (Figure 
20). We also wondered whether the low concentration of grazoprevir was 
effective or not in removing HCV when co-administered with the NS5A 
inhibitor. Previous reports showed grazoprevir concentration in the blood to be 
approximately 8.8-15.2 nM after 24 hours of administration (C24) of 200 mg 
of grazoprevir, we used 15 nM concentration of grazoprevir to see the 
combination effect at colony formation assay.[81] 
 
 
Figure 21. Colony formation assay for combination with grazoprevir on S52 




We treated the major compounds with C24 concentration of grazoprevir, 
about 15 nM, resulting in a synergistic effect of colony elimination levels 
(Figure 21).[81] Those results suggest that the occurring of resistance mutant 
caused by the single administration of the NS5A inhibitor can be got over by 
the combined administration of other DAA’s.  
(CI > 1: antagonism effect. CI=1: additive effect, CI <1: synergistic effect). 
 
Docking study 
Through our investigation, we have seen that proline and fluorene moieties 
play an important role in inhibiting wild type HCV and resistance mutant HCV. 
Additionally, in order to relate in-vitro study results with in-silico docking study, 
we computationally performed the docking analysis for association between 






EC50 (nM) Docking score (Kcal/mol) 
WT D.M. WT D.M. 
47 
(BMK-21054) 
0.0016 41.4 -8.22 -6.26 
54 
(BMK-21075) 
0.0296 0.058 -9.48 -7.04 
 
 
Figure 22. Docking studies of an inhibitor compound and NS5A dimer model 
(NS5A domain 1 PDB ID: 3FQQ, 1ZH1; AH helix NMR structure PDB ID: 
1R7G) (a) docking score for compound 47 and 54 (b) compound 47 and NS5A 




We used two kinds of NS5A domain 1 structures and AH region for docking 
analysis (NS5A Domain 1 PDB ID: 3FQQ, 1ZH1; AH helix NMR structure 
PDB ID: 1R7G). The docking score proposes that 3FQQ model was well fitted 
with NS5A inhibitor than 1ZH1 model (Figure 22a). Also, the docking analysis 
could predict the possible interaction residues between NS5A inhibitor and 
NS5A protein which are likely to bind to each of inhibitors with hydrophobic 
or hydrophilic interactions. We used NS5A with a daclatasvir resistance mutant 
and expected that V31 residue would interact with fluorene core region since 
alkylchain of 9-position in fluorene core region inhibited L31V resistance 
mutant in assay results, but unlike our expectation, the V31 residue was 
observed to be located on the phenyl glycine region at docking results. 
Although these results were different with our expectations, it had a part of 
consensus with the previously reported by Michael W. Parker group report.[80] 
The other daclatasvir resistance mutation, the H93 residue, was well in 
agreement with our conjecture because the 4-hydrosyl-L-proline of compound 
54 interacts with H93 of the NS5A protein via hydrogen bond (Figure 22b and 
21c). Taken together, through the docking analysis, we suggest a possibility that 
in-vitro assay results could be proved as docking score. Also, we could infer 
that docking score might in part reflect the assay results in terms of efficacy of 
compounds on resistance mutant HCV. Furthermore, it should be noted that, it 
was beyond our scope to do docking analysis for NS5A inhibitor and genotype 





In conclusion, we developed novel structure of NS5A inhibitors based on a 
fluorene derivatives and proline-amide skeleton. Additionally, we could 
observe the relationship between the specific part such as fluorene moiety or L-
proline of our inhibitors and NS5A protein for inhibiting HCV replication. 
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Finally, among variously designed inhibitors, we found a few inhibitors to be 
shown highly effective response on genotype 1b and 3a HCV as well as on 





Materials and Method 
Without additional notes, all reagents were commercially available and used 
without further purification. THF was distilled over sodium and benzophenone, 
and degassed by argon bubbling for 10 minutes before using on polymerization. 
Toluene, 1,4-dioxane, methanol, DMF were purified by solvent purification 
system using alumina column, and degassed by argon bubbling. N,N’-
dimethylacetamide (DMA) was purchased from Junsei and degassed by argon 
for 10 minutes before using on polymerization without further purification. 
 
DNA constructs and in-vitro transcription of RNA 
 
NK5.1-Gluc 
For inserting the Gaussia luciferase gene to NK5.1 clone, we used site direct 
mutagenesis (SDM) PCR to generate restriction enzyme site (Asc1) between 
HCV IRES and Neomycin phosphotransferase region. The FMDV (Foot and 
Mouth disease virus) 2A protease fused Gaussia luciferase gene was amplified 
using PCR. This amplified 2A-Gluc-2A PCR product containing Asc1 site was 
digested with restriction enzyme and ligated with NK5.1 (Figure 16). To 
synthesize the replicon RNA, it was linearized by Sca1 and in-vitro transcribed 
RNA using T7 polymerase. 
 
JC1-Gluc 
For inserting the 2A-Gluc-2A between P7 and NS2 region of JC1 clone, we 
used Site direct mutagenesis (SDM) PCR to generate restriction enzyme site 
(Asc1) between P7 and NS2 region. The FMDV (Foot and Mouth disease virus) 
2A protease fused Gaussia luciferase gene was amplified using PCR. This 
amplified 2A-Gluc-2A PCR product containing Asc1 site was digested with 
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restriction enzyme and ligated with JC1 (Figure 16). To synthesize the RNA, it 
was linearized by Xba1 and in-vitro transcribed RNA using T7 polymerase. 
 
S52-Feo 
Dr. Charles M. Rice kindly provided the S52-Feo (genotype 3a). To synthesize 
the RNA, it was linearized by Xba1 and in-vitro transcribed RNA using T7 
polymerase. 
 
Measurement of the anti-HCV activities of inhibitors using HCVcc 
 
Cell line and cell culture 
Huh 7.5.1 cells were grown in Dulbecco’s Modified Eagle’s medium (DMEM; 
Gibco) supplemented with antibiotics (100 U/mL penicillin, 10 g/mL 
streptomycin) and 10% fetal bovine serum (FBS; PEAK) at 37°C in a 
humidified 6.0% CO2 incubator. 
 
Virus production 
In vitro transcribed HCV RNA were electrophoresed in Huh 7.5.1 cell as 
described previously. Briefly, the transfected cells were maintained with 
culture media for three days and then the culture media containing HCV 
were collected for 7 days and then filtered through a 0.45 μM pore size filter.  
 
Antiviral activity test with infectious HCV particles 
Huh 7.5.1 cells were inoculated with a JC1-Gluc virus for 4h. At 4h after the 
virus inoculation, HCV-infected Huh7.5.1 cells were cultivated with media 
containing serially diluted inhibitors. At 3 days post chemical treatment, the 
culture media was harvested and Gaussia luciferase activities were measured 
using a Renilla luciferase assay system (Promega) according to the 
manufacturer’s direction. The luciferase activities were normalized to those 
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obtained from mock-treated cells. A four parameter Logistic of the SigmaPlot 
Program was used for calculating the EC50 value and Statistics Value. 
 
Measurement of anti-HCV activities of inhibitors using HCV 
replicon 
 
Cell line and cell culture 
Huh 7.5.1 cells containing a bicistronic HCV replicon NK5.1-Gluc (genotype 
1b) and S52-Feo (genotype 3a) were used to test the anti-HCV activities of the 
inhibitors (Figure 16). In-vitro transcribed replicon RNA (30 μg) was 
transfected to Huh7.5.1 cell and then inoculated with G418 (0.5 mg/ml, 
Calbiochem) containing DMEM media for selecting HCV RNA replicating cell. 
After this selection prosess, the selected replicon-containing cells were 
cultivated under DMEM media supplemented with antibiotics (100 U/mL 
penicillin, 10 g/mL streptomycin) and 10% fetal bovine serum (FBS; PEAK) 
and additional antibiotic G418 (0.5 mg/ml, Calbiochem). 
 
Antiviral activity assay test with HCV replicon 
HCV replicating cells were seeded on a 12-well plate (5 x 104 cells per well). 
One day later, the replicon cells were replaced with fresh media containing 
serially diluted inhibitors and incubated for three days. To measure the 
luciferase activity of NK5.1-Gluc replicon cell, 3 day post treatment cell culture 
media were collected and Gaussia luciferase activities were measured using 
Renilla luciferase assay system (Promega).  
In the case of 3a replicon cell (S52-Feo), Luciferase activities were measured 
using cell lysate by firefly luciferase assay system (Promega) according to the 
manufacturer’s direction, and then normalized to those obtained from mock-
treated (0.1% DMSO) cells. A four parameter logistic of the SigmaPlot Program 




Observation of the effects of co-treatment of two inhibitors  
The HCV replicating cells were treated with each of inhibitors alone or with 
mixtures of grazoprevir at serially diluted concentrations. At 3 days after 
treatment, luciferase activities were measured using the luciferase assay system 
(Promega) according to the manufacturer’s direction, and then normalized to 
those obtained from mock-treated (0.1% DMSO) cells. Combination index was 
calculated by using Compusyn Freeware Program (Compusyn, Inc.). 
 
Colony formation assay 
Huh 7.5.1 cells containing HCV replicon (NK5.1-Gluc or S52-Feo) were used 
for colony formation assay. HCV replicon cells were seeded on a 6 well plates 
(5 x 104 cells per well). At 16hr after plating, culture media was replaced with 
fresh media containing serially diluted compound without G418 for 5 days. 
When cell confluence reaches ~95% after 5 days, the cells were split into two 
6 well plates. About 20% confluence cells were plated with inhibitor containing 
DMEM media without G418. About 25% confluence cell was maintained in the 
other plate with DMEM media containing 1mg/ml G418. Cell culture media 
was changed with fresh one in every two or three days. Two weeks after, the 
cells, which were selected by G418, was fixed with a solution of 1% 
formaldehyde and 1% methanol and 0.5g crystal violet solution for 20 min and 
washed with PBS. After drying the plate, we took a picture using Amersham™ 
Imager 600 (GE healthcare). 
 
Antiviral assay test using resistance mutant HCV 
We substituted amino acid codon to L31V, Y93H and L31V+Y93H of NS5A 
protein of NK5.1-Gluc genome using site direct mutagenesis PCR. It was 
linearized with Scal restriction enzyme and used as in-vitro transcription. In-
vitro transcribed mutant RNA were electrophoresed to Huh 7.5.1 cells 
individually and seeded in a 12 well plate. One day later, the transfected cells 
were replaced with fresh culture media containing serially diluted compounds 
and incubated for 3 days. 3 days post treatment, cell culture media was collected 
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and Gaussia luciferase activities were measured using Renilla luciferase assay 
system (Promega). Luciferase activities were normalized to those obtained 
from mock-treated (0.1% DMSO) cell. A four parameter Logistic of the 
SigmaPlot Program was used for calculating the EC50 value and Statistics Value. 
 
Cytotoxicity test 
To determine the cytotoxicity effect of tested inhibitors, Huh 7.5.1 cells were 
seeded on 24 wells plate (2 x 104 cells per well). One day later, culture media 
was replaced with DMEM media containing serially diluted inhibitors and 
inoculated for three days. Post treatment, the culture supernatant harvested from 
each well and centrifuged to remove cell debris (12,000 rpm, 4’C, 10 min). 
Using cell supernatant, the cytotoxicity level was measured using 
ToxiLight™(Lonza) kit according to manufacturer’s directions. 
 
Docking analysis 
All experiments of docking analysis were performed by Korea Institute of 
Science and Technology (KIST)  
 
Humanized liver mice test 








1. A. M. Di Bisceglie, The Lancet, 1998, 351, 351-355. 
2. A. U. Neumann, N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley, T. J. 
Layden and A. S. Perelson, Science, 1998, 282, 103-107. 
3. T. L. Tellinghuisen, J. Marcotrigiano and C. M. Rice, Nature, 2005, 435, 
374-379. 
4. G. L. Davis, M. J. Alter, H. El-Serag, T. Poynard and L. W. Jennings, 
Gastroenterology, 2010, 138, 513-521, 521 e511-516. 
5. D. Lavanchy, Liver Int., 2009, 29 Suppl 1, 74-81. 
6. M. Zajac, I. Muszalska, A. Sobczak, A. Dadej, S. Tomczak and A. Jelinska, 
Eur. J. Med. Chem., 2019, 165, 225-249. 
7. N. Arima, C. Y. Kao, T. Licht, R. Padmanabhan, Y. Sasaguri and R. 
Padmanabhan, J. Biol. Chem., 2001, 276, 12675-12684. 
8. H. R. Rosen, N. Engl. J. Med., 2011, 364, 2429-2438. 
9. G. M. Lauer and B. D. Walker, N. Engl. J. Med., 2001, 345, 41-52. 
10. Y. Huang, K. Staschke, R. De Francesco and S.-L. Tan, Virology, 2007, 
364, 1-9. 
11. K.-H. Lan, M.-L. Sheu, S.-J. Hwang, S.-H. Yen, S.-Y. Chen, J.-C. Wu, Y.-
J. Wang, N. Kato, M. Omata, F.-Y. Chang and S.-D. Lee, Oncogene, 2002, 
21, 4801-4811. 
12. R. Bartenschlager, V. Lohmann and F. Penin, Nat. Rev. Microbiol., 2013, 
11, 482-496. 
13. S. A. Qureshi, Med. Res. Rev., 2007, 27, 353-373. 
14. M. U. Ashraf, K. Iman, M. F. Khalid, H. M. Salman, T. Shafi, M. Rafi, N. 
Javaid, R. Hussain, F. Ahmad, S. Shahzad-Ul-Hussan, S. Mirza, M. Shafiq, 
S. Afzal, S. Hamera, S. Anwar, R. Qazi, M. Idrees, S. A. Qureshi and S. U. 
Chaudhary, Med. Res. Rev., 2019, 39, 1091-1136. 
15. I. H. Bae, J. K. Choi, C. Chough, S. J. Keum, H. Kim, S. K. Jang and B. 
M. Kim, ACS Med. Chem. Lett., 2014, 5, 255-258. 
16. N. Horscroft, V. C. H. Lai, W. Cheney, N. Yao, J. Z. Wu, Z. Hong and W. 
123 
 
Zhong, Antiviral Chem. Chemother., 2005, 16, 1-12. 
17. T. L. Tellinghuisen, M. J. Evans, T. von Hahn, S. You and C. M. Rice, J. 
Virol., 2007, 81, 8853-8867. 
18. A. Aghemo and R. De Francesco, Hepatology, 2013, 58, 428-438. 
19. R. A. Fridell, D. Qiu, C. Wang, L. Valera and M. Gao, Antimicrob. Agents. 
Chemother., 2010, 54, 3641-3650. 
20. M. Gao, R. E. Nettles, M. Belema, L. B. Snyder, V. N. Nguyen, R. A. 
Fridell, M. H. Serrano-Wu, D. R. Langley, J. H. Sun, D. R. O'Boyle, 2nd, 
J. A. Lemm, C. Wang, J. O. Knipe, C. Chien, R. J. Colonno, D. M. Grasela, 
N. A. Meanwell and L. G. Hamann, Nature, 2010, 465, 96-100. 
21. C. Wang, H. Huang, L. Valera, J.-H. Sun, D. R. O'Boyle, II, P. T. Nower, 
L. Jia, D. Qiu, X. Huang, A. Altaf, M. Gao and R. A. Fridell, Antimicrob. 
Agents Chemother., 2012, 56, 1350-1358. 
22. R. A. Love, O. Brodsky, M. J. Hickey, P. A. Wells and C. N. Cronin, J. 
Virol., 2009, 83, 4395-4403. 
23. A. Chan, K. Patel and S. Naggie, Drugs, 2017, 77, 131-144. 
24. C. Tateno, Y. Kawase, Y. Tobita, S. Hamamura, H. Ohshita, H. Yokomichi, 
H. Sanada, M. Kakuni, A. Shiota, Y. Kojima, Y. Ishida, H. Shitara, N. A. 
Wada, H. Tateishi, M. Sudoh, S. Nagatsuka, K. Jishage and M. Kohara, 
PloS one, 2015, 10, e0142145. 
25. V. K. Rustgi, Expert Opin. Drug Saf., 2010, 9, 883-892. 
26. M. Belema, V. N. Nguyen, D. R. St. Laurent, O. D. Lopez, Y. Qiu, A. C. 
Good, P. T. Nower, L. Valera, D. R. O'Boyle, J.-H. Sun, M. Liu, R. A. 
Fridell, J. A. Lemm, M. Gao, J. O. Knipe, N. A. Meanwell and L. B. Snyder, 
Bioorg. Med. Chem. Lett., 2013, 23, 4428-4435. 
27. R. A. Fridell, C. Wang, J. H. Sun, D. R. O'Boyle, 2nd, P. Nower, L. Valera, 
D. Qiu, S. Roberts, X. Huang, B. Kienzle, M. Bifano, R. E. Nettles and M. 
Gao, Hepatology, 2011, 54, 1924-1935. 
28. S. Pol, R. H. Ghalib, V. K. Rustgi, C. Martorell, G. T. Everson, H. A. Tatum, 
C. Hezode, J. K. Lim, J.-P. Bronowicki, G. A. Abrams, N. Braeu, D. W. 
Morris, P. J. Thuluvath, R. W. Reindollar, P. D. Yin, U. Diva, R. Hindes, F. 
124 
 
McPhee, D. Hernandez, M. Wind-Rotolo, E. A. Hughes and S. Schnittman, 
Lancet Infect. Dis., 2012, 12, 671-677. 
29. S. Zeuzem, M. Mizokami, S. Pianko, A. Mangia, K.-H. Han, R. Martin, E. 
Svarovskaia, H. Dvory-Sobol, B. Doehle, C. Hedskog, C. Yun, D. M. 
Brainard, S. Knox, J. G. McHutchison, M. D. Miller, H. Mo, W.-L. Chuang, 
I. Jacobson, G. J. Dore and M. Sulkowski, J. Hepatol., 2017, 66, 910-918. 
30. M. C. Sorbo, V. Cento, V. C. Di Maio, A. Y. M. Howe, F. Garcia, C. F. 
Perno and F. Ceccherini-Silberstein, Drug Resistance Updates, 2018, 37, 
17-39. 
31. D. R. O'Boyle Ii, J. H. Sun, P. T. Nower, J. A. Lemm, R. A. Fridell, C. 
Wang, J. L. Romine, M. Belema, V. N. Nguyen, D. R. Laurent, M. Serrano-
Wu, L. B. Snyder, N. A. Meanwell, D. R. Langley and M. Gao, Virology, 
2013, 444, 343-354. 
32. K. Vercauteren, Y. P. de Jong and P. Meuleman, Curr. Opin. Virol., 2015, 
13, 67-74. 
33. D. R. St. Laurent, M. Belema, M. Gao, J. Goodrich, R. Kakarla, J. O. 
Knipe, J. A. Lemm, M. Liu, O. D. Lopez, V. N. Nguyen, P. T. Nower, D. 
O'Boyle, Y. Qiu, J. L. Romine, M. H. Serrano-Wu, J.-H. Sun, L. Valera, F. 
Yang, X. Yang, N. A. Meanwell and L. B. Snyder, Bioorg. Med. Chem. 
Lett., 2012, 22, 6063-6066. 
34. D. J. Cada, J. Leonard, T. L. Levien and D. E. Baker, Hosp. Pharm., 2015, 
50, 396-412. 
35. A. M. Bell, J. L. Wagner, K. E. Barber and K. R. Stover, Int. J. Hepatol., 
2016, 2016, 3852126. 
36. E. B. Chahine, D. Kelley and L. M. Childs-Kean, Ann Pharmacother., 
2018, 52, 352-363. 
37. P. McCormack, Drugs, 2015, 75, 515-524. 
38. D. Ross-Thriepland and M. Harris, J. Gen. Virol., 2015, 96, 727-738. 
39. S. Giroux, J. Xu, T. J. Reddy, M. Morris, K. M. Cottrell, C. Cadilhac, J. A. 
Henderson, O. Nicolas, D. Bilimoria, F. Denis, N. Mani, N. Ewing, R. 
Shawgo, L. L'Heureux, S. Selliah, L. Chan, N. Chauret, F. Berlioz-Seux, 
125 
 
M. N. Namchuk, A. L. Grillot, Y. L. Bennani, S. K. Das and J. P. Maxwell, 
ACS Med. Chem. Lett., 2014, 5, 240-243. 
40. M. Zhong, E. Peng, N. Huang, Q. Huang, A. Huq, M. Lau, R. Colonno and 
L. Li, Bioorg. Med. Chem. Lett., 2014, 24, 5731-5737. 
41. M. Issur and M. Götte, Viruses, 2014, 6, 4227-4241. 
42. A. V. Ivachtchenko, O. D. Mitkin, P. M. Yamanushkin, I. V. Kuznetsova, 
E. A. Bulanova, N. A. Shevkun, A. G. Koryakova, R. N. Karapetian, V. V. 
Bichko, A. S. Trifelenkov, D. V. Kravchenko, N. V. Vostokova, M. S. 
Veselov, N. V. Chufarova and Y. A. Ivanenkov, J. Med. Chem., 2014, 57, 
7716-7730. 
43. Y. You, H. S. Kim, J. W. Park, G. Keum, S. K. Jang and B. M. Kim, RSC 
Advances, 2018, 8, 31803-31821. 
44. J. J. Kohler, J. H. Nettles, F. Amblard, S. J. Hurwitz, L. Bassit, R. A. 
Stanton, M. Ehteshami and R. F. Schinazi, Infect. Drug. Resist., 2014, 7, 
41-56. 
45. D. B. Ascher, J. Wielens, T. L. Nero, L. Doughty, C. J. Morton and M. W. 
Parker, Sci. Rep., 2014, 4, 4765. 
46. E. P. Gillis, K. J. Eastman, M. D. Hill, D. J. Donnelly and N. A. Meanwell, 
J. Med. Chem., 2015, 58, 8315-8359. 
47. J. Dong, K. B. Sharpless, L. Kwisnek, J. S. Oakdale and V. V. Fokin, 
Angewandte Chemie, 2014, 53, 9466-9470. 
48. J. Dong, L. Krasnova, M. G. Finn and K. B. Sharpless, Angewandte 
Chemie, 2014, 53, 9430-9448. 
49. S. Li, L. T. Beringer, S. Chen and S. Averick, Polymer, 2015, 78, 37-41. 
50. A. Narayanan and L. H. Jones, Chem. Sci., 2015, 6, 2650-2659. 
51. J. Yatvin, K. Brooks and J. Locklin, Chemistry, 2016, 22, 16348-16354. 
52. A. Dondoni and A. Marra, Org Biomol Chem, 2017, 15, 1549-1553. 
53. I. H. Bae, H. S. Kim, Y. You, C. Chough, W. Choe, M. K. Seon, S. G. Lee, 
G. Keum, S. K. Jang and B. Moon Kim, Eur. J. Med. Chem., 2015, 101, 
163-178. 
54. D. R. St Laurent, M. H. Serrano-Wu, M. Belema, M. Ding, H. Fang, M. 
126 
 
Gao, J. T. Goodrich, R. G. Krause, J. A. Lemm, M. Liu, O. D. Lopez, V. 
N. Nguyen, P. T. Nower, D. R. O'Boyle, 2nd, B. C. Pearce, J. L. Romine, 
L. Valera, J. H. Sun, Y. K. Wang, F. Yang, X. Yang, N. A. Meanwell and L. 
B. Snyder, J. Med. Chem., 2014, 57, 1976-1994. 
55. T. R. Webb and C. Eigenbrot, J. Org. Chem., 1991, 56, 3009-3016. 
56. K. S. Lim, D. W. Kang, Y. S. Kim, M. S. Kim, S. G. Park, S. Choi, L. V. 
Pearce, P. M. Blumberg and J. Lee, Bioorg Med Chem Lett, 2011, 21, 299-
302. 
57. L. C. King and G. K. Ostrum, J. Org. Chem., 1964, 29, 3459-3461. 
58. S. D. Schimler, M. A. Cismesia, P. S. Hanley, R. D. Froese, M. J. Jansma, 
D. C. Bland and M. S. Sanford, J. Am. Chem. Soc., 2017, 139, 1452-1455. 
59. R. Zelli, S. Tommasone, P. Dumy, A. Marra and A. Dondoni, Euro. J. Org. 
Chem., 2016, DOI: 10.1002/ejoc.201600732, 5102-5116. 
60. Y. You, H. S. Kim, I. H. Bae, S. G. Lee, M. H. Jee, G. Keum, S. K. Jang 
and B. M. Kim, Eur. J. Med. Chem., 2017, 125, 87-100. 
61. C. S. Kim, S. J. Keum and S. K. Jang, PloS one, 2011, 6, e22808. 
62. B. D. Lindenbach, M. J. Evans, A. J. Syder, B. Woelk, T. L. Tellinghuisen, 
C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating and 
C. M. Rice, Science, 2005, 309, 623-626. 
63. C. Wang, L. Jia, H. Huang, D. Qiu, L. Valera, X. Huang, J. H. Sun, P. T. 
Nower, D. R. O'Boyle, 2nd, M. Gao and R. A. Fridell, Antimicrob. Agents 
Chemother., 2012, 56, 1588-1590. 
64. M. Belema, O. D. Lopez, J. A. Bender, J. L. Romine, D. R. St Laurent, D. 
R. Langley, J. A. Lemm, D. R. O'Boyle, 2nd, J. H. Sun, C. Wang, R. A. 
Fridell and N. A. Meanwell, J. Med. Chem., 2014, 57, 1643-1672. 
65. S. Li, D. Cohen-Karni, L. T. Beringer, C. Wu, E. Kallick, H. Edington, M. 
J. Passineau and S. Averick, Polymer, 2016, 99, 7-12. 
66. P. Targett-Adams, E. J. S. Graham, J. Middleton, A. Palmer, S. M. Shaw, 
H. Lavender, P. Brain, T. D. Tran, L. H. Jones, F. Wakenhut, B. Stammen, 
D. Pryde, C. Pickford and M. Westby, J. Virol., 2011, 85, 6353-6368. 
67. F. Penin, V. Brass, N. Appel, S. Ramboarina, R. Montserret, D. Ficheux, 
127 
 
H. E. Blum, R. Bartenschlager and D. Moradpour, J. Biol. Chem., 2004, 
279, 40835-40843. 
68. C. A. Coulson, Nature, 1969, 221, 1106-1110. 
69. J. Shi, L. Zhou, F. Amblard, D. R. Bobeck, H. Zhang, P. Liu, L. Bondada, 
T. R. McBrayer, P. M. Tharnish, T. Whitaker, S. J. Coats and R. F. Schinazi, 
Bioorg. Med. Chem. Lett., 2012, 22, 3488-3491. 
70. B. T. Guan, X. Y. Lu, Y. Zheng, D. G. Yu, T. Wu, K. L. Li, B. J. Li and Z. 
J. Shi, Org Lett, 2010, 12, 396-399. 
71. K. J. Blight, A. A. Kolykhalov and C. M. Rice, Science, 2000, 290, 1972-
1974. 
72. T. C. Chou, Pharmacol. Rev., 2006, 58, 621-681. 
73. T.-C. Chou, Cancer Res., 2010, 70, 440. 
74. R. Schinazi, P. Halfon, P. Marcellin and T. Asselah, Liver Int., 2014, 34 
Suppl 1, 69-78. 
75. D. R. Piper, S. R. Duff, H. C. Eliason, W. J. Frazee, E. A. Frey, M. 
Fuerstenau-Sharp, C. Jachec, B. D. Marks, B. A. Pollok, M. S. Shekhani, 
D. V. Thompson, P. Whitney, K. W. Vogel and S. D. Hess, Assay. Drug. 
Dev. Technol., 2008, 6, 213-223. 
76. V. Lohmann, F. Korner, J. Koch, U. Herian, L. Theilmann and R. 
Bartenschlager, Science, 1999, 285, 110-113. 
77. T. Phan, R. K. Beran, C. Peters, I. C. Lorenz and B. D. Lindenbach, J. 
Virol., 2009, 83, 8379-8395. 
78. A. Geddawy, Y. F. Ibrahim, N. M. Elbahie and M. A. Ibrahim, J. Transl. 
Int. Med., 2017, 5, 8-17. 
79. C. Wang, J. H. Sun, D. R. O'Boyle, 2nd, P. Nower, L. Valera, S. Roberts, 
R. A. Fridell and M. Gao, Antimicrob. Agents. Chemother., 2013, 57, 2054-
2065. 
80. M. O. Silva, M. Treitel, D. J. Graham, S. Curry, M. J. Frontera, P. 
McMonagle, S. Gupta, E. Hughes, R. Chase, F. Lahser, R. J. O. Barnard, 
A. Y. M. Howe and J. A. Howe, J. Hepatol., 2013, 59, 31-37. 
81. T. T. Cheung, J. W. Yan Chiu, M. F. Yuen, K. S. Ling Lam, B. M. Yung 
128 
 
Cheung, H.-P. Feng, W. W. Yeh, J. Wang, W. Li, X. M. Zhao, Z. Wang and 







C 형 간염 바이러스 (HCV) 감염은 간경화 및 간암으로 이어질 
수 있으며, 결국 사망에 이를 수 있는 심각한 질환이다. 최근 
HCV의 여러 유전자형을 표적으로 하는 직접 작용 제제들 (DAA)을 
개발하기위한 노력이 집중되어왔다. 특히, 비 구조 단백질 5A 
(NS5A)는 HCV 증식에 필수적이므로, 여러 제약회사에서 NS5A를 
타겟으로 하는 항HCV 약물을 많이 개발하고 있다. 우리는 이 
논문에서, 바이아릴 설폰 (biaryl sulfone) 또는 황산염 (biaryl 
sulfate) 중심과 치환된 플루오렌 (fluorene) 중심골격을 가진 
새로운 C 형 간염 바이러스 비 구조 5A (NS5A)단백질 억제제를 
개발하였다. 
첫째, 우리는 황산염 코어 구조를 함유 한 HCV NS5A 억제제의 
합성을 위해, 불화 황 (VI) 불화 교환 (SuFEx) 반응으로 알려진 
아릴 설포닐 플루오라이드 (aryl sulfonyl fluride)와 아릴 실릴 
에테르 (aryl silyl ether)사이의 고효율 화학적 커플링 반응을 
이용하여 합성하였다. SuFEx화학에 기초하여 합성한 억제제 중, 
몇몇 화합물은 GT-1b에 대한 두 자리 pM 수준의 EC50 값 및 
HCV GT-2a 균주에 대한 nM 수준보다 낮은 EC50 값활성을 
나타내었다. 황산염 중심골격의 각 면에 이미다졸 (imidazole) 및 
아마이드 (amide)부분을 함유하는 비대칭 억제제 또한 합성하였다. 
설페이트 또는 설폰 코어 구조의 다양한 치환 패턴을 함유하는 
억제제에 대한 구조-활성 관계 (SAR) 연구을 통해, 아마이드 
잔기를 함유한 BMK-21014 또는 이미다졸 잔기를 함유하는 BMK-
21025 은 매우 높은 저해활성을 보여주었다. BMK-21014 는 
유전자형 1b (GT-1b)와 2a (GT-2a)에 대해, 두자리 수 pM 수준의 
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저해 활성도를 나타냈다. BMK-21025 는 GT-1b에 비해 두 
자리수의 pM 및 GT-2a에 대한 nM보다 낮은 EC50 를 보여주었다. 
또한, BMK-21014 및 BMK-21025 는 hERG 리간드 결합 분석에서 
심장 독성을 나타내지 않았으며, 에임스 (Ames)시험에서 돌연변이 
유발 가능성을 나타내지 않았다. 이들 화합물은 비구조 단백질 5B 
(NS5B) 억제제인 sofosbuvir (Sovaldi®) 약물과의 병용 치료에서 
부가 효과가 있는 것으로 나타났다. 이 연구의 결과를 바탕으로, 
바이아릴 설페이트 중심 골격을 갖는 화합물이 효과적인 HCV 
억제제가 될 수 있음을 보여 주었다. 
한편, 최근에 개발된 NS5A 억제제들은 돌연변이에 의해 생기는 
저해제 내성이 큰 이슈로 부각되고 있다. 특정 유전자형과 낮은 
저항 장벽에 대한 낮은 저해 활성도를 극복하기 위해, 우리는 
NS5A 저해제의 다양한 유도체를 개발하고 in vitro 및 in vivo 분석 
시스템을 사용하여 HCV 증식에 미치는 영향을 조사했다. 그 
중에서, 유전자형 3a와 약물 내성 돌연변이에 효과적인 화합물 
BMK-21054 와 BMK-21075 를 개발할 수 있었다. 이러한 결과를 
바탕으로, 우리는 플루오렌 중심골격과 치환된 L-프롤린 유도체를 
가진 NS5A 억제제가 다양한 HCV 유전자형과 돌연변이 억제에 
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